Health Dictionary

Overview

Extra-abdominal desmoid tumor must be differentiated from fibrosarcoma, low-grade fibromyxoid sarcoma and Gardner fibroma. Intra-abdominal desmoid tumor must be differentiated from gastrointestinal stromal tumor (GIST), benign fibrous tumor/solitary fibrous tumor (SFT), inflammatory myofibroblastic tumor (IMT), sclerosing mesenteritis and retroperitoneal fibrosis. Furthermore, generally all desmoid tumors must be differentiated from acute hematoma, lymphoma, rhabdomyosarcoma, liposarcoma, leiomyosarcoma, neurofibroma, nodular fasciitis, hypertrophic scars,keloids and primitive neuroectodermal tumor.

Differentiating Desmoid tumor from other Diseases

Extra-abdominal fibromatosis/desmoid tumor must be differentiated from:^[1]^[2]^[3]^[4]^[5]^[6]
- Fibrosarcoma/fibroblastic sarcoma
- Low-grade fibromyxoid sarcoma
- Gardner fibroma
Intra-abdominal fibromatosis must be differentiated from:^[7]
- Gastrointestinal stromal tumor (GIST)
- Benign fibrous tumor/Solitary fibrous tumor (SFT)
- Inflammatory myofibroblastic tumor (IMT)
- Sclerosing mesenteritis
- Retroperitoneal fibrosis due to:^[8]
  - Idiopathic [Ormond’s disease]
  - Secondary to certain drugs
  - Underlying malignancy such as lymphoma
Furthermore, generally all desmoid tumors must be differentiated from:

**Differentiating desmoid tumor from other diseases**
Disease entity	Etiology (Genetic or others)	Histopathological findings	Immunohistochemical staining	Benign/Malignant	Risk factors	Common site of involvement	Clinical manifestations	Other associated features
Desmoid tumor	Sporadic desmoids are associated with following mutations: Wnt/beta-catenin signaling pathway Mutations in CTNNB1 (Beta-catenin gene) (85%) APC gene mutations (10-15%) Familial desmoids/Hereditary desmoid disease is associated with: Mutation in second copy of APC gene Pediatric desmoids have following additional mutations involving: AKT1 E17K (31%) BRAF V600E (19%) TP53 R273H (9%)	Histologically, desmoid tumors consist of: Linearly arranged elongated fibroblasts and myofibroblasts Characterized by elongated, tapered cytoplasm; elongated, vesicular, typical-appearing nuclei; and multiple small nucleoli Surrounded and separated from each other by collagen	Positive for: Nuclear beta-catenin (90%) Vimentin Alpha smooth muscle actin Muscle actin Negative for: Desmin Cytokeratins S-100 c-KIT	Benign High local aggressive infiltration High local recurrence	Familial adenomatous polyposis (FAP) Gardner syndrome (inherited desmoids) Turcot syndrome Specific location of APC (adenomatous polyposis coli) gene mutation i.e. 3′ end of the APC gene, specifically between codons 1445 and 1580 Family history of desmoid tumor Family history of colon cancer/FAP Estrogen therapy Oral contraceptive pills Pregnancy History of antecedent surgical/accidental trauma at the tumor site (30%) History of breast cancer History of repeated irradiation to a certain body part Female gender Sex hormones/androgens	Abdominal wall (intra-abdominal desmoids) Extra-abdominal desmoids may involve: Shoulder girdle Upper arms Upper legs Hip/buttock region Trunk Head Neck Breast (history of breast cancer/breast surgery Intra-abdominal desmoids may involve: Mesentery Retroperitoneum Bowel	Asymptomatic Painless/painful lump in affected area Pain or soreness caused by compressed nerves or muscles Limping or other difficulty using the legs, feet, arms or hands Decreased movement or range of motion Nausea Vomiting Breast mass (in case of breast desmoids) Loss of sleep Anxiety Abdominal mass/pain Constipation Bloating Intestinal rupture Rectal bleeding Compression of kidneys, ureters, mesenteric vessels and vena cava	Desmoids may be associated with following: Other sporadic tumors such as: Dupuytren’s contracture Plantar fibrosis Peyronie’s disease Carpal tunnel syndrome Infantile fibrosarcoma Fibrous dysplasia Trisomy 8 Trisomy 20
Fibrosarcoma/Fibroblastic sarcoma	Unknown precise cause Genetics may play a role	Tumor cells resemble mature fibroblasts (spindle-shaped), secreting collagen, with rare mitoses Spliting and merging cells arranged in short fascicles giving “fish bone” appearnace Immature blood vessels (lacking endothelial cells) favor the bloodstream metastasizing “Herringbone” pattern of cell arrangement	Strongly positive for: Vimentin Negative for: Desmin Smooth muscle actin HHF35 Osteocalcin CD68 LCA S100 HMB45 CD31 CD34 Cytokeratin Epithelial membrane antigen CD99	Malignant (with metastatic potential)	Familial adenomatous polyposis Li-Fraumeni syndrome Neurofibromatosis type 1 Nevoid basal cell carcinoma syndrome Retinoblastoma Tuberous sclerosis Werner syndrome Giant cell tumor Enchondroma Fibrous dysplasia Bizarre parosteal osteochondromatous proliferation Chronic osteomyelitis Paget’s disease Radiation therapy Surgically treated fracture Bone infarction Exposure to certain chemicals, such as thorium dioxide, vinyl chloride, or arsenic Lymphedema, a swelling in the arms and legs	Primary bone malignancy involving end of long bones: Upper end of tibia Lower end of femur	Localized pain Swelling Loss of range of motion Pain with weight-bearing Night pain Pathologic fracture of affected bone	Moth-eaten appearance on X-ray
Low-grade fibromyxoid sarcoma^[4]^[5]^[9]^[10]^[11]^[12]^[13]^[14]	Translocation: t(7;18;16) or t(7;16) (q34:p11) Fusion gene: FUS/CREB3L2 (76%-96%) FUS/CREB3L1 (4%-6%)	Low to moderate cellularity Regular medium sized nuclei Loosely arranged fascicles of bland spindle cells (whorling pattern) Loose myxoid stroma No cellular atypia Hypocellular/myxoid areas in nodules merging with collagenised areas	Positive for: MUC4 (highly specific and sensitive) Vimentin Occasionally positive for: Desmin SMA EMA CD34 Negative for: Keratin Actin S100 Epithelial membrane antigen CD31 CD68 Cytokeratin (AE1/AE3) Leu7 Neuron-specific enolase	Benign (histological appearance) High metastasizing potential/local aggressive infiltration High local recurrence	_	Majority occurring in subfascial location and rarely involving subcutis or dermis in following sites: Lower extremities Trunk Groin Upper extremities Thorax Buttocks Abdominal wall Maxillofacial region (rarely)	Painless, slow-growing well-circumscribed mass Average size-5cm (ranges from 1-20cm)	_
Benign fibrous tumor /Solitary fibrous tumor (SFT) ^[15]^[16]^[17]^[18]^[19]^[20]^[21]^[22]^[23]	Intra-chromosomal inversion at: Chromosome 12q13 leading to formation of NAB2–STAT6 chimeric fusion gene (highly variable breakpoints) TERT promoter mutations responsible for: High aggressive potential Metastatic potential	Fibroblast-like tumor cells arranged in a “patternless” pattern Collagenous stroma with staghorn, hyalinized blood vessels Increased mitotic activity Hypercellularity Nuclear atypia Pleomorphism Lipomatous, myxoid, or dedifferentiated variants	Positive for: CD34 Vimentin CD99 (013) Bcl-2 In few cases, positive for: Focal keratin reactivity Focal desmin reactivity Negative for: CD31 Cytokeratin Glial fibrillary acidic protein Smooth muscle actin S-100 protein Epithelial membrane antigen	Metastatic and highly aggressive (10%-20%) (due to TERT promotor mutations) Recurrence (10%-20%)	_	Any anatomic site Serosal membranes such as: Pleura (most common site) Dura of the meninges Peritoneum (or peritoneal cavity) Thoracic cavity (mediastinum, lung parenchyma) Intra-abdominal SFTs involve: Retroperitoneal soft tissue (most common) Liver Diaphragm Pelvic visceras (bladder, prostate, seminal vesicle, kidney) Head and neck sites include: Sinonasal tract Oral cavity Orbit Buccal mucosa Tongue Lower lip Extremities Skin (dermis) Bone	Asymptomatic Pulmonary symptoms (cough, shortness of breath, chest pain, hemoptysis, obstructive pneumonitis because of airway obstruction) Intra-abdominal symptoms (pain,weight loss, dysuria, urinary retention, hydronephrosis, nocturia, constipation, incontinence, vomiting) Paresthesias Symptoms due to nerve impingement Meningeal symptoms Hypoglycemia (due to paraneoplastic syndromes) Symptoms due to hypertrophic pulmonary osteoarthropathy include: Clubbing of fingers Periostitis Synovial effusions	Paraneoplastic syndromes associated with SFTs include: Doege-Potter syndrome (Refractory hypoglycemia due to IGF2, associated with large peritoneal/pleural tumors) Hypertrophic pulmonary osteoarthropathy (HPO)/Pierre-Marie-Bamberger syndrome( in pleuropulmonary SFTs, secretes hyaluronic acid, cytokines)
Gardner fibroma/Gardner-associated fibroma (GAF)^[24]^[25]^[6]^[26]	APC gene mutation	Thick haphazardly arranged collagen bundles (greater abundance of collagen) Few interspersed spindle cells of fibroblast type (less cellularity)	Positive for: Nuclear Beta-catenin (highly positive) CD34 Cyclin-D1 C-myc	Benign	Gardner-type familial adenomatous polyposis Germline mutations in APC gene Inherited desmoids Gardner syndrome The presence of nuchal-type fibroma may indicate Gardner Fibroma, when seen in children	Any part of body: Back (most common) Paraspinal region (most common) Chest wall Abdomen Head Neck Arms Legs	Firm rubbery mass (not a well-circumscribed) Size from 1-10 cm Signs and symptoms due to associated FAP or Gardner syndrome	Precursor lesion for desmoid (50% cases) with a more cellular appearance Precursor lesion for colonic adenomas in asymptomatic FAP patients
Gastrointestinal stromal tumor (GIST)^[27]^[28]^[29]^[30]^[31]	Activating mutation of: C-KIT ( tyrosine kinase growth factor receptor) gene (Exon 9,13 & 17) Platelet-derived growth factor receptor alpha (PDGFRA on chromosome 4q11-12) gene (Exon 18) BRAF kinase (rare) Protein kinase C (rare) Pediatric GISTs (SDH–deficient) have mutations of one of the: SDH (succinate dehydrogenase)gene subunits GIST as a part of Carney triad has following mutation: Hypermethylation of the SDHC promoter causing epigenetic inactivation of the SDHC gene Wild-type GISTs have following three molecular subtypes: DHX mutations (66%) SDHC promoter hypermethylation (22%) SDH competent (12%) which can further be broken into: NF1 mutations BRAF V600E mutations Other rare mutations or fusions No identified abnormality	GIST cells basically arise from interstitial cells of Cajal (ICCs) and appear as follows on histology: Spindle cells (60%-80%): Fascicular or whorled like appearance Multiple compact cells with minimal stroma Eosinophilic, basophilic or amphophilic cytoplasm Epithelioid cells (20%-30%) Clearly defined with an abundant amphophilic cytoplasm Pleomorphic/mixed cells (occasionally, 10%) Both spindle or epitheloid cells	Positive for: CD117 (overexpression of the receptor tyrosine kinase KIT is the most prominent diagnostic test) CD34 DOG-1 PKC-theta (protein kinase C theta) Consistently negative for: Beta-catenin	Malignant potential (esophageal and colonal GIST) Metastasis (to liver, lungs, bones, subcutis, spleen)	Age group of 50-80years Primary familial GIST syndrome Neurofibromatosis type 1 (NF1) Carney-Stratakis syndrome (dyad of GISTs and paragangliomas) Carney triad (GIST, paraganglioma, and pulmonary chondromas) Urticaria pigmentosa	Can involve any part of GIT: Stomach (most common) Duodenum Omentum Mesentery Esophagus Colon Peritoneum	Depending on tumor size and localization in GIT: Pain Nausea Vomiting Bleeding Obstruction Anemia Melena Abdominal distension Abdominal perforation Peritonitis Volvulus Intussusception Surgical complications associated with resection include: Atelectasis Pneumonia Urinary tract infection Abscess formation Small-bowel obstruction Deep venous thrombosis	_
Inflammatory myofibroblastic tumor (IMT)^[32]^[33]^[34]^[35]^[36]^[37]^[38]^[39]^[33]^[36]^[7]	Unknown underlying etiology, may be due to inflammatory reaction to: Infection Underlying low grade malignancy Mutations such as: ALK (anaplastic lymphoma kinase) gene mutations in the tyrosine kinase locus at band 2p23	Spindle to stellate-shaped cells Spindle cells arranged in short fascicles with a focal storiform (whorled or cartwheel-like) architecture Spindle cells show features of fibroblasts and myofibroblasts Variably dense, chronic, mixed polymorphic infiltrate of mononuclear inflammatory cells (plasma cells and lymphocytes, histiocytes, neutrophils, and occasional eosinophils) Histiocytes have multinucleated forms with finely vacuolated cytoplasmic lipid droplets Plasma cells with cytoplasmic Russell bodies (globular cytoplasmic inclusions of immunoglobulin) and polyclonal pattern of light chain expression Absent hyperchromasia and atypical mitoses	Positive for: IG+ (plasma cells) IL-1 IL-6 Smooth muscle actin Desmin Calponin Activin-like kinase 1 Negative for: Beta-catenin	Metastatic	Multiorgan disease in association with chronic persistent Eikenella corrodens infection Epstein Barr virus infection Human herpes virus-8(HHV-8) infection (Kaposi’s sarcoma, multicentric Castleman’s disease)	Lungs Gastrointestinal system Pelvic region Bladder Uterus Retroperitoneum Skin Bone (femur, temporal bone, jaw bone) CNS Soft tissues Larynx Heart (right ventricle is most commonly involved) Pancreas (rarely)	Asymptomatic (70%) Painless asymptomatic mass/lump/swelling Pulmonary IMT presents as: Chest pain Cough Dyspnea Hemoptysis (recurrent) Fever Fatigue Weight loss Appetite loss Bone IMT presents with: Mild bone pain Easy fractures Headache Dizziness Numbness at tumor site Bone marrow involvement in some cases Heart IMT presents with: Chest pain Difficulty breathing Palpitations Fainting Obstruction of blood flow in the heart (large tumors) Bladder IMT presents with: Painless hematuria Chronic pelvic pain Difficulty in urinating Presence of burning sensation CNS IMT presents with: Presence of solitary or multiple tumors at various locations in the brain Recurrent headaches Headache Nausea and vomiting Blurred vision Double vision Drooping of the eyelid Dizziness Back pain (if spine involved) Seizures	Also known as: Pseudo-inflammatory tumors Inflammatory pseudotumor Plasma cell granuloma Inflammatory pseudotumor Fibrous histiocytoma Fibroxanthoma Xanthogranuloma Inflammatory pseudosarcoma Atypical fibromyxoid tumor Atypical myfibroblastic tumor
Sclerosing mesenteritis^[40]^[41]^[42]^[43]^[44]^[45]^[46]^[47]^[48]^[49]^[50]^[51]^[52] ^[53]^[54]^[55]^[56]^[57]^[58]^[59]^[60]	Unknown exact etiology: Encompasses a spectrum of idiopathic primary inflammatory and fibrotic processes affecting mesentery	Varying components of: Inflammation, fibrosis, and fat necrosis Adipocyte necrosis (mesenteric lipodystrophy) Chronic inflammatory state (mesenteric panniculitis) Fibrosis (sclerosing mesenteritis)	_	Non-neoplastic inflammatory and fibrotic disease	Abdominal surgery/trauma: Cholecystectomy Appendectomy Hysterectomy Colectomy Pneumatic jackhammer Occult ileal perforation Autoimmunity: Riedel thyroiditis Primary sclerosing cholangitis Retroperitoneal fibrosis Orbital pseudotumor Autoimmune hemolytic anemia Minimal change nephropathy Systemic lupus erythematosus Relapsing polychondritis Multifocal fibrosclerosis Limited systemic sclerosis Celiac-associated T-cell lymphoma Paraneoplastic syndrome: Non-Hodgkin lymphoma(most common) Breast cancer Carcinoid Melanoma Squamous carcinoma and adenocarcinoma of the lung Renal carcinoma Multiple myeloma Hepatocellular carcinoma Prostate adenocarcinoma Ovarian carcinoma Endometrial carcinoma Cervical carcinoma Angiosarcoma Gastrointestinal adenocarcinomas Ischemia and infection history: Typhoid fever Dysentery Tuberculosis Syphilis Malaria Influenza Rheumatic fever	Mesentery	Asymptomatic Abdominal pain Nausea and vomiting Altered bowel habits (constipation or diarrhea) Weight loss Fever Malaise Abdominal tenderness Abdominal distension Peritoneal inflammation and ascites (usually chylous) Pleural effusion Protein-losing enteropathy (fever, edema) Biliary obstruction (hemolytic anemia, jaundice) Bowel obstruction Obstructive uropathy/renal failure Chylous ascites Chronic mesenteric ischemia Anemia Hypoalbuminemia Mesenteric vascular occlusion (both arterial and venous)	Nomenclature used in the medical literature for idiopathic primary inflammatory and fibrotic processes of the mesentery is as follows: Mesenteric lipodystrophy (predominant fat necrosis predominance) Mesenteric fibrosis Mesenteric panniculitis Mesenteric lipodystrophy Retractile mesenteritis Mesenteric Weber-Christian disease Xanthogranulomatous mesenteritis Mesenteric lipogranuloma Liposclerotic mesenteritis Inflammatory pseudotumor Isolated lipodystrophy Retroperitoneal xanthogranuloma
Retroperitoneal fibrosis^[61]^[62]^[63]^[64]^[65]^[66]^[67]^[68]^[69]^[70]^[71]^[72]^[73]	Idiopathic (70%) [Ormond’s disease] is an immune-mediated disease caused by: Other autoim mune diseases Immunoglobul in G4-related disease (IgG4-RD) Chronic periaortitis Allele HLA‑DRB1*03, D32 polymorphism of the gene encoding CCR5 (chemokine receptor) TTCCAT haplotype of the gene encoding CCL11/eotaxin‑1 (drives the recruitment of eosinophils) Secondary to: Certain drugs Underlying malignancy such as lymphoma	Fibro-inflammatory disease histologically hallmarked by fibrous tissue and chronic inflammation: Fibrous tissue composed of extracellular matrix containing type I collagen fibers organized in thick irregular bundles, often encircling small retroperitoneal vessels Fibroblasts: Show signs of activation and transition into myofibroblasts (α‑smooth muscle actin expression) Are major source of collagen production Rarely show mitoses, undergo clonal proliferation Inflammatory infiltrate consists of numerous lymphocytes, plasma cells, and macrophages Inflammatory cells maybe: Interspersed within the collagen bundles (“diffuse” pattern) or Organized in nodular aggregates, usually around small vessels, having a B cell core surrounded by CD4+ T cells When IgG4+/total IgG+ plasma cell ratio is >40%, RPF is classified as “IgG4-related” if other features such as storiform fibrosis, eosinophil infiltration, and obliterative phlebitis are also present	Tryptase positive (mast cells)	Benign immune mediated inflammatory process	Idiopathic [Ormond’s disease] Secondary to certain drugs (ergot-derivatives, methysergide, bromocriptine, beta blockers, methyldopa, hydralazine, analgesics) Biological agents (etanercept, infliximab) Underlying malignancy (carcinoid, Hodgkin and non-Hodgkin lymphoma, sarcomas, colorectal, breast, prostate and bladder carcinoma ) Infections (tuberculosis, histoplasmosis, actinomycosis) Radiation therapy for testicular seminoma, colon and pancreatic cancer Retroperitoneal hemorrhage Surgery (lymphadenectomy, colectomy, aortic aneurysmectomy) Secondary (AA) amyloidosis Trauma Barium enema Mesenteric panniculitis Different forms of histiocytosis particularly Erdheim-Chester disease Exposure to asbestos Tobacco smoke exposure	Thoracic aorta Mesenteric arteries Renal arteries and veins Epiaortic arteries Ureters Abdominal organs Pancreas Salivary glands Lymph nodes Pituitary gland	Pain in the lower back, abdomen, or flank (most common presentation, bilateral or unilateral flank pain that radiates to the inguinal region, or acute onset pain similar to renal colic) Abdominal aortic aneurysms Malaise Anorexia Weight loss Fever Nausea and vomiting Testicular pain Constipation Venous compression (inferior vena cava) leading to: Lower limb edema (lymphatic compression) Inferior vena cava syndrome Deep vein thrombosis Pulmonary embolism Arterial stenosis (rare) causing: Upper-leg claudication Mesenteric ischemia (mesenteric arteries compression) Thoracic aorta and/or the epi-aortic arteries‘ compression Recurrent laryngeal nerve paralysis causing hoarseness and dry cough Acute kidney injury (AKI) (due to bilateral encasement of ureteral and renal involvement in peri-iliac retroperitoneal fibrosis) Renal atrophy (due to previous transient unilateral obstruction or renal artery stenosis) Obstructive uropathy Gross hematuria Urinary symptoms (urinary urgency,frequency, and dysuria) Hypertension (due to renal artery impingement) Obstruction of the inferior vena cava and/or iliac veins Thrombophlebitis Deep vein thrombosis Varicocele Hydrocele	Retroperitoneal fibrosis is also known as: Ormond’s disease Periureteritis fibrosa Periureteritis plastica Chronic periureteritis Sclerosing retroperitoneal granuloma Fibrous retroperitonitis
Lymphoma	Diffuse large B cell lymphoma (DLBCL): Rare MALT1 rearrangements, trisomy 18 in some, possible NFκB activation in minority Extranodal marginal B cell lymphoma arising from mucosal associated lymphoid tissue (MALT lymphoma): Clonal rearrangements of immunoglobulin genes Often trisomy 3, 12, 18 Usually negative for characteristic MALT1 rearrangements t(11;18)(q21;q21) and t(14;18)(q32;q21) Follicular lymphoma: Presence of t(14;18)(q32;q21) translocation has not been systematically assessed in primary breast follicular lymphoma Burkitt lymphoma: t(8;14)(q24;q32) c-Myc and IgH translocation is most frequent t(2;8)(p12;q24) IgΚ and c-Myc t(8;22)(q24;q11) c-Myc and Igλ	Diffuse large B cell lymphoma (DLBCL): Diffuse infiltration by large lymphoid cells, centroblastic > immunoblastic, activated B cell type > germinal center type Extranodal marginal B cell lymphoma: Vaguely nodular growth pattern, neoplastic cells occupy the marginal zone surrounding the B cell follicle mantle zone but can have diffuse growth pattern if follicles infiltrated / replaced Marginal zone B cells, variable plasma cells, reactive follicles (±) Monocytoid-like cells Plasmacytic differentiation Low mitotic rate Follicular lymphoma: Follicular and diffuse architectural patterns Monotonous population of small cleaved cells (centrocytes) Variable numbers of centroblasts (large noncleaved cells) Associated sclerosis can cause single file infiltration pattern Burkitt lymphoma: Sheets of uniform medium sized lymphocytes with round nuclei, multiple basophilic nucleoli, coarse chromatin, scant to moderate basophilic cytoplasm, minimal intervening stroma High mitotic rate Tingible body macrophages containing apoptotic debris produce a “starry sky” appearance Mantle cell lymphoma: Small to medium sized, slightly irregular cells with scant cytoplasm Classic Hodgkin lymphoma: Reed-Sternberg cells and variants in a reactive background Nodular lymphocyte predominant Hodgkin lymphoma: Vague nodules of small B cells and interspersed large tumor cells (LP cells) with thin nuclear membranes, fine chromatin and variable nucleoli MALT lymphoma: Infiltration of thyroid epithelium creates lymphoepithelial lesions (lymphocytes “stuff” glandular lumina) May have background lymphocytic thyroiditis	Positive for: Diffuse large B cell lymphoma (DLBCL): CD45, CD20, CD79a, PAX5, BCL2, Ki67 (high) Activated B cell type (CD10-, BCL6– or CD10-, BCL6+, MUM1 / IRF+) is more common Germinal center type (CD10+, BCL6+ or CD10-, BCL6+, MUM1 / IRF-) Surface Ig+ CD43± Extranodal marginal B cell lymphoma arising from mucosal associated lymphoid tissue (MALT lymphoma): Surface and cytoplasmic Ig+ (IgM > IgG or IgA) CD45, CD20, CD79a, PAX5, variable CD43, variable BCL2, Ki67 (low) Variable monotypic cytoplasmic immunoglobulin seen in cases with plasmacytic differentiation CD21 and CD23 highlight expanded / disrupted follicular dendritic meshworks CD43± Follicular lymphoma: Surface Ig+ CD45, CD20, CD79a, CD10, BCL6, BCL2 CD21 and CD23 highlight follicular dendritic cell meshworks Burkitt lymphoma: Surface IgM+ CD45, CD20, CD79a, PAX5, CD10, BCL6, Ki67 (~100%) Mantle cell lymphoma: Surface IgMD+, CD20+, CD5+, CD10-, CD43+, cyclin D1+ Classic Hodgkin lymphoma: R-S cells: CD30+, CD15±, PAX5+ Nodular lymphocyte predominant Hodgkin lymphoma: LP cells: CD45+, CD20+ Thyroid MALT lymphoma: CD20 Keratin Thyroglobulin CD45 Anaplastic large T cell lymphoma: CD3, CD10, CD30, CD43, CD99, TdT PreT lymphoblastic lymphoma: CD3, CD10, CD99, TdT Negative for: Diffuse large B cell lymphoma (DLBCL): EBER Extranodal marginal B cell lymphoma, MALT type: CD5, CD10, CD23, BCL6, cyclin D1 Follicular lymphoma: CD5, CD23, cyclin D1 Burkitt lymphoma: CD5, CD23, TdT, BCL2 Mantle cell lymphoma: CD10– Classic Hodgkin lymphoma: R-S cells: ALK-, CD45-, CD3– Nodular lymphocyte predominant Hodgkin lymphoma: LP cells: CD15-, CD30– Anaplastic large T cell lymphoma: ALK1, bcl6 PreT lymphoblastic lymphoma: Bcl6-	Malignant	MALT lymphoma (Extranodal marginal B cell lymphoma may arise from it) Underlying autoimmune disease EBV (endemic and sporadic Burkitt lymphoma) HIV (immunodeficiency associated Burkitt lymphoma) HHV-8 Chronic hepatitis C infection Transplants Chemotherapy	Anywhere in body Lymph nodes Esophagus Bladder Bone Oral cavity Thyroid gland	Painless palpable mass, with or without ipsilateral lymphadenopathy Fever Night sweats Weight loss Neck mass Dysphagia Odynophagia Chest / abdominal pain Weight loss Hemorrhage Vocal cord paralysis / hoarseness Stricture / obstruction Perforation with esophagomediastinal or esophagotracheobronchial fistula or mediastinitis Cold nodule	WHO classification of lymphoma: Hodgkin lymphomas arise from precursor B cells (Reed-Sternberg cells) Classic Hodgkin lymphoma (CHL) – 95% is further subclassified as: Nodular sclerosis Lymphocyte rich Mixed cellularity Lymphocyte depleted Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) – 5% Non-Hodgkin lymphomas arise from monoclonal expansion of malignant B or T cells B cell lymphomas B cell acute lymphoblastic lymphoma (ALL) Chronic lymphocytic lymphoma / small lymphocytic leukemia (CLL / SLL) Mantle cell lymphoma Follicular lymphoma Marginal zone B cell lymphoma Extranodal MALT type Hairy cell leukemia Plasmacytoma / plasma cell myeloma Diffuse large B cell lymphoma (DLBCL) Burkitt lymphoma T / NK cell lymphomas T cell acute lymphoblastic lymphoma (ALL) T cell CLL Mycosis fungoides / Sézary syndrome Peripheral T cell lymphoma Angioimmunoblastic T cell lymphoma Enteropathy associated intestinal T cell lymphoma Hepatosplenic T cell lymphoma Anaplastic large cell lymphoma (ALCL) Extranodal NK / T cell lymphoma, nasal type
Rhabdomyosarcoma (RMS)^[74]^[75]^[76]^[77]^[78]^[79]^[80]^[81]^[82]^[83]	MyoD1 and PIK3CA mutation (sclerosing and spindle cell RMS) Most common translocation is t(2;13)(q35;q14), causing PAX3‘FOXO1 gene fusion (alveolar RMS) t(1;13)(p36;q14), causing PAX7‘FOXO1 gene fusion Embryonal RMS is associated with: Loss of heterozygosity (LOH) at 11p15 locus (site of IGF-2 gene) Other genes at 11p15.5 locus: H19 CDKN1C HOTS Other mutations include pRb, TP53, GLI, CDKN2A, CDKN2B, RAS, FGFR4, PIK3CA, CTNNB1 [beta-catenin] and NF1 genes VGLL2 and NCOA2 rearrangements Gene fusions include VGLL2-CITED2, VGLL2-NC0A2, TEAD1-NCOA2, PAX3-NCOA2, PAX3-NCOA2, and SRF-NCOA2 Further gene mutations include: RAS RB1 PTCH MDM2 CDK4 MYCN Basic helix-loop-helix [bHLH]	Histologic classification: Embryonal RMS comprises of: Rhabdomyoblasts arranged in sheets and large nests, with infrequent intermixed fusiform cells Myofilaments with cross-striations Botryoid (sarcoma botryoides) and spindle cell (leiomyomatous) RMS: “Grape-like” gross appearance of the tumor Polypoid mass grows beneath an epithelial surface, with dense subepithelial aggregates of rhabdomyoblasts (the so-called “cambrium” layer) Sclerosing and spindle cell RMS Alveolar RMS comprises of: Fibrovascular septae lined with densely packed ovoid to round tumor cells separated by pseudo-alveolar spaces (vaguely resemble pulmonary alveoli) “Loosely adherent” rhabdomyoblasts shed into these pseudo-alveolar spaces Anaplastic RMS comprises of: Large hyperchromatic nuclei with atypical bizarre mitotic figures Nuclear size is threefold larger than that of adjacent “typical” tumor cells	Positive for: Actin Myosin Desmin Myoglobin Z-band protein Myogenic differentiation 1 (MyoD1) Maybe positive for: Cytokeratin Synaptophysin Neuron-specific enolase S-100 protein	Malignant soft tissue tumor Metastatic	In utero radiation exposure Accelerated in utero growth Low socioeconomic status Antibiotics receival soon after birth Recreational drugs usage during pregnancy Neurofibromatosis Li-Fraumeni syndrome Beckwith-Wiedemann syndrome Costello syndrome	Head and neck (orbit, parameningeal sites including middle ear, nasal cavity, paranasal sinuses, nasopharynx, infratemporal fossa, scalp, parotid gland, oral cavity, pharynx, thyroid and parathyroid glands) Genitourinary tract (bladder, prostate, or the male or female genital tracts) Sarcoma botryoides (urinary bladder wall, vagina, nasopharynx) Extremity Trunk Chest wall Perineal-perianal region Biliary tract Liver Brain Trachea Heart Breast Ovary	Proptosis Ophthalmoplegia Nasal, aural, or sinus obstruction with or without a mucopurulent or sanguineous discharge Localized, painless enlarging mass Hematuria Large pelvic mass Urinary obstruction Urinary frequency Constipation Mucosanguineous vaginal discharge Polypoid mass protruding from vagina Scrotal or inguinal enlargement (paratesticular tumors)	Histology of RMS similar to that of other childhood small round blue cell tumors involving bone and soft tissue such as: Lymphoma Small cell osteosarcoma Mesenchymal chondrosarcoma Ewing sarcoma family of tumors (EFT)
Liposarcoma^[84]^[85]^[86]^[87]^[88]^[89]^[90]^[91]^[92]^[93]	Atypical lipomatous tumor/well differentiated liposarcoma and dedifferentiated liposarcoma are associated with: Presence of a large/giant marker chromosome and/or ring chromosomes at 12q13-15 region Amplification of this chromosome region rich in protooncogenes, including CHOP, CDK4, MDM2, HMGI-C, GLI, SAS, OS1, HMGA2 and OS9 Myxoid liposarcoma is associated with: t(12:16)(q13;p11) – CHOP(DDIT3) / FUS or t(12;22)(q13;q22) – CHOP(DDIT3) / EWS Pleomorphic liposarcoma is associated with: Complex karyotypic aberrations	Well-differentiated liposarcoma: Sclerosing liposarcoma (distinctive stromal cells distributed across the tissue, associated with lipoblasts filled with multiple vacuoles, and collagenous background of fibrillary appearance) Adipocytic liposarcoma (adipocytes with different cell sizes, hyperchromasia, and nuclear atypia. Fibrous septa containing hyperchromatic stromal cellssurrounding adipocytes) Inflammatory liposarcoma (heavy chronic inflammatory infiltrate composed of different lympho-plasmacytic aggregates) Spindle cell liposarcoma (proliferation of neural-like spindle cells organized in a fibrous structure containing lipoblasts) De-differentiated liposarcoma: Myxoid liposarcoma ( non-homogenous appearance with cystic and solid components) Round cell liposarcoma ( small, round, or spindle cells with sparse eosinophilic and granular cytoplasm and large nuclei,scattered lipoblasts and areas of necrosis) Pleiomorphic liposarcoma (pleiomorphic cells with enlarged round to bizarre nuclei)	Atypical lipomatous tumor/well differentiated liposarcoma is positive for: MDM2 CDK4 p16 S100 (stains adipocytes and lipoblasts)	Round cell liposarcoma metstasizes to retroperitoneum, pleural cavity, soft tissue, or pelvis and lungs (poor prognosis)	Chemical carcinogens Phenoxyacetic herbicides Chlorophenols Dioxin contaminations Arsenic Thorium dioxide (Thorotrast) Radiation (dose of 50 GY) Immunodeficiency (regional acquired immunodeficiency) Genetic susceptibility Li-Fraumeni syndrome Neurofibromatosis (NF1; von Recklinghausen disease) Gardner syndrome (Familial adenomatous polyposis) Retinoblastoma Werner syndrome Nevoid basal cell carcinoma (Gorlin syndrome) Viral infections	Retroperitoneum Esophagus Bowel Mediastinum	Retroperitoneal liposarcoma maybe asymptomatic or causes: Weight loss Abdominal pain Oliguria renal failure (due to ureters or kidneys‘ compression) Palpable abdominal mass Abdominal tenderness Abdominal distention Esophageal liposarcoma may cause: Dysphagia Vomiting Cough Gastrointestinal bleeding Hoarseness Bowel liposarcoma may cause: Gastrointestinal bleeding Mediastinal liposarcoma may cause: Dyspnea Cough Chest pain Weight loss	_
Leiomyosarcoma^[94]^[95]^[96]^[97]^[98]^[99]^[100]^[101]^[102]	Loss of normal chromosome 1q (hereditary leiomyomatosis) Renal cell cancer (HLRCC) gene mutation	Prominent cellular atypia Nuclear atypia, including nuclear pleomorphism, hyperchromatism, irregularity in nuclear membranes, high nuclear size, and prominent nucleoli Cigar-shaped nuclei Abundant mitoses, mitotic index higher than 10 or more per 10 high-power fields Areas of coagulative necrosis (tumor cell necrosis) Palisading and extensive degenerativechanges in the form of hyalinization, calcification, and myxoid changes Elongated cells with eosinophilic or occasional fibrillar cytoplasm with distinct cell membranes	Positive for: HHF35 (90%) Alpha-smooth muscle actin (90%) Vimentin Desmin (75%) H-caldesmon PTAH (stains myofibrils) Keratin (30%) ER (usually in uterine and female retroperitoneal tumors) S100 (occasionally weak staining) EMA (may be focal) CD34 Negative for: CD117	Malignant Metastatic to lungs, liver, blood vessels, or any other soft tissue in the body	Immundeficiency (HIV) Digoxin exposure Human herpes virus type-8 (HHV-8) Epstein barr virus Long term tamoxifen use History of pelvic radiations Hereditary breast carcinoma with BRCA1 mutation Hereditary nonpolyposis colorectal carcinoma with MSH2 mutation Li-Fraumeni syndrome Malignant melanoma Retinoblastoma	Uterus Abdomen Esophagus Rectum Skin / subcutis Retroperitoneum Extremities Large vessels (inferior vena cava, saphenous vein, femoral vein, pulmonary artery, femoral artery) Superficial or deep soft tissues Bone Breast Colon Epididymis Mediastinum Lungs	Asymptomatic (uterine leiomyosarcoma may be associated with: Irregular vaginal bleeding (intermenstrual or postmenopausal) New lump or a mass protruding into vagina or growing mass in abdomen or pelvis Abdominal pain Abdominal distension Pelvic pain Urinary symptoms Esophageal leiomyosarcoma may cause: Dysphagia Hematemesis rectal leiomyosarcoma may cause: Black, tarry stools Rectal bleeding	_
Neurofibroma^[103]^[104]^[105]^[106]^[107]^[108]^[109]^[106]^[110]^[111]^[112]	Can be sporadic or as a part of Neurofibromatosis 1 and 2 NF1 gene located at chromosomal region 17q11.2, codesforneurofibromin Functional part of neurofibromin GAP (or GTPase-activating protein) accelerates the conversionof the active GTP-bound RAS to its inactive GDP-bound form Loss of RAS controlleads to increased activity of other signaling pathwaysincluding RAF, ERK1/2, PI3K, PAK, MAPK, SCF/c-kit and mTOR-S6 kinase	Uniphasic, low to moderate cellularity No peripheral perineural capsule Random pattern, only rare palisading No well formed verocy bodies Hypocellular with abundant mucinous/myxoid matrix without hypercellular areas Frequent mast cells Contains neural fibroblasts and fibrillary or shredded carrot collagen Random proliferation of Schwann cellsand scattered admixed axons No nevoid cells No epithelial component Diffuse growth pattern Scant cytoplasm Wavy spindle cells with buckled nuclei Pseudomeissnerian bodies representing specific differentiation may be present Lacks storiform pattern Neurofibroma with degenerative atypia(“ancient change“) has following microscopic features: Localized cells with large pleomorphic nuclei, cytoplasmic nuclear inclusions, smudgy chromatin, and inconspicuous nuclei Absent or very low mitotic activity Low to moderate cellularity	Positive for: S100 (weaker) SOX10 Neurofilament (and Bielshowsky) GFAP CD34 (stronger) Factor XIIIa Calretinin (focal) MBP (myelin–basic protein) Negative for: EMA (except in plexiform neurofibromas)	Cutaneous neurofibromas are always benign Diffuse neurofibromas can become malignant	Neurofibromatosis 1 Neurofibromatosis 2 (multiple neurofibromas, meningiomas of the brain or spinal cord, and ependymomas of the spinal cord)	Anywhere in body Scalp (diffuse neurofibroma)	Soft masses/bumps on or under skin (internal or superficial) Transient itching (mast cellsrelease histamine) Transient pain Numbness and tingling in the affected area Severe bleeding (sign of tumor growth) Physical disfiguration Cognitive disability Stinging Neurological deficits Changes in movement(clumsiness in hands, trouble walking) Bowel incontinence Scoliosis (an abnormal curvature of the spine, if the tumor creates muscular imbalance or erodes bones of the spine) Following symptoms may occur with genitourinary tractinvolvement (rarely): Urinary tract infection (most common clinicalmanifestation) Urinary retention Urinary frequency Urgency Hematuria Pelvic mass Hydronephrosis Urinary incontinence(decreased bladder capacity or compliance) Appears as a focal mass or diffuse bladder wall thickening in case of a plexiform neurofibroma	Nerve often not identified, incorporates nerve, axonsoften present in lesion Seldom cystic Frequently multiple Widespread soft tissue infiltration Tends to displace adnexa <2cm in diameter Lacks distinct lobulation Lacks fat Affects individuals between 20-40 years of age Men and women are equallyaffected Plexiform neurofibroma are thought to be congenital and occur earlier in life
Nodular fasciitis^[113]^[114]^[115]^[116]^[117]^[118]^[119]^[120]^[121]^[122]	Balanced translocation t(17;22)(p13;q13) resulting in MYH9–USP6 gene fusion	Histologically vast array of patterns Fibroblasts, spindle-shaped cells found in connective tissue Myofibroblasts, large cells with an appearance between fibroblasts and smooth muscle tissue Sub-membranous “tram track” pattern characteristic of myofibroblasts on immunostaining Short C or S-shaped fascicles or cartwheel formations Feathery appearance cells, with holes or tears in the tissue Visible chromosomes in cells during cell division Fine, pale, and even-looking chromatin Inflammation, accelerated mitotic index with normal mitoses Non-pleomorphic cells with high rate of mitosis Essentially spindle cell proliferation Stroma is rich in collagen and/or myxoid ground substance	Positive for: Smooth muscle actin Muscle specific actin Vimentin Calponin CD68 Negative for: S100 Desmin Keratin CD34 Caldesmon ALK p53	Benign	Reparative process secondary to trauma	Anywhere in body Arms (34%) Flexor forearm (27%) Head and neck region (24%) Trunk (chest, back) (21%) Thigh (17%) Legs (14%) Upper arm (12%) Hands (rarely) Bladder Breast Cervix Intra-articular Prostate Vagina Vulva	Solitary firm non-painful mass Oval or round in shape with irregular margins Tender (maybe)	Also known as: Nodular pseudosarcomatous fasciitis Subcutaneous pseudosarcomatous fibromatosis Pseudosarcomatous fasciitis
Hypertrophic scars	Overexpression of growth factors such as: TGF-beta VEGF CTGF Decreased production of matrix metalloproteinases Increased numbers of PDGF receptors on fibroblasts Over-activation of signals for insulin-like growth factor-1 Decreased fibroblast apoptosis rate Increased expression of thymic stromal lymphopoietin Increased fibrocyte activation via stromal cell-derived factor-1 Genes in four susceptibility loci on chromosomes 1q41, 3q22.3-23, and 15q21.3	Excess collagen formation with varying numbers of fibroblasts and myofibroblasts Collagen fibers are arranged in a wavy pattern predominantly oriented parallel to the epithelial surface Nodular structures containing myofibroblasts and vertically aligned vessels	_	Benign	Frequent complication of burn injuries Piercings Cuts Surgical wounds Lacerations Adverse wound healing factors at the injury site such as: Infection (acne, folliculitis, chicken pox, and vaccinations) Excessive tension	Milder than keloids Don’t grow beyond the boundaries of the original skin injury	Cosmetic disfigurement Pruritis Pain Functional impairment (from contracture or mechanical irritation) Loss of temperature regulation Dry skin Neuropathic pain	Hypertrophic scars can be classified as: Mature scar Immature scar Linear, hypertrophic scar (surgical/traumatic) Widespread, hypertrophied scar (burn)
Keloids^[123]^[124]^[125]^[126]	Epigenetic alteration in fibroblast DNA and acetylation of histone proteins Overexpression of growth factors such as: TGF-beta VEGF CTGF Decreased production of matrix metalloproteinases Increased numbers of PDGF receptors on fibroblasts Over-activation of signals for insulin-like growth factor-1 Decreased fibroblast apoptosis rate Increased expression of thymic stromal lymphopoietin Increased fibrocyte activation via stromal cell-derived factor-1 Genes in following susceptibility loci on chromosomes: 1q41 3q22.3-23 15q21.3 2q23 7p11 10q23.31 In Japanese population, 4 SNP loci (rs873549, rs1511412, rs940187, and rs8032158) in 3 chromosomal regions (1q41, 3q22.3–23, and 15q21.3) exhibit significant associations with keloids	Hyalinized collagen bundles Excess collagen formation with varying numbers of fibroblasts and myofibroblasts Hypocellular zones of fibrous tissue containing thickened, glassy, eosinophilic collagen bundles	_	Benign	Minor injuries Insect bites Pimples Earlobe piercings Adverse wound healing factors at the injury site such as: Infection Inflammation Excessive tension Excessive motion (such as in injuries over a joint), Wound left to heal without stitches Keloids may be associated with rare inherited syndromes such as: Rubinstein-Taybi syndrome Goeminne syndrome	Any part of body having injury Upper chest Shoulders Upper back Head and neck (especially on ears)	Cosmetic disfigurement Raised, reddish nodules Skin pigmentation Itchiness Redness Unusual sensations Pain Functional impairment	Keloid is Greek for “crab claw” Extend beyond the borders of the original wound Regress spontaneously Recur after excision Darkly pigmented people/African-American, Asians (Han Chinese, Japanese) are more prone to form keloids Keloids can be prevented by using: Pressure dressing Silicone gel pad Paper tape over the injury site for 23-24hours per day Keloids can be classified as: Minor keloid Major keloid
Primitive neuroectodermal tumor (PNET)^[127]^[128]^[129]	EWS / FLI1 fusion product by RT-PCR due to t(11;22)(q24/q22;q12) (90%) p53 tumor suppressor gene mutations	Small blue cell tumor Round hyperchromatic cells Abundant mitotic figures Homer Wright rosettes Fibrosis Neurosecretory granules on electron microscopy	Positive for: CD99 FLI1 PAS+ diastase sensitive (glycogen) Vimentin Neuron specific enolase Negative for: Cytokeratin (usually) Desmin WT1 GFAP PAX2	Malignant neural crest tumor Highly aggressive (rapid death within 1 year) Metastases to lung, pleura, bone and liver	Gorlin syndrome Turcot syndrome Coffin-Siris syndrome Cowden syndrome Gardner syndrome Li-Fraumeni syndrome Rubinstein-Taybi syndrome	CNS PNET: Intracranial (cerebral hemisphere) Peripheral PNET: kidneys	Asymptomatic for years Morning headache Restlessness Recurrent vomiting Diplopia Frequent falls Positional dizziness Increased intracranial pressure Seizures Papilledema Strabismus Nystagmus Ataxia Motor weakness Facial sensory loss Third, fourth, and sixth cranial nerve palsies Abdominal/flank pain Hematuria	Also known as: CNS PNET Askin tumor Peripheral neuroepithelioma Ependymoblastoma WHO classified PNET into 3 subtypes: Central primitive neuroectodermal tumors (PNETs) Neuroblastomas Peripheral primitive neuroectodermal tumors (pPNETs) Peripheral PNET (pPNET) is now thought to be virtually identical to Ewing sarcoma

Reference

↑ Economou, Athanasios; Pitta, Xanthi; Andreadis, Efstathios; Papapavlou, Leonidas; Chrissidis, Thomas (2011). “Desmoid tumor of the abdominal wall: a case report”. Journal of Medical Case Reports. 5 (1): 326. doi:10.1186/1752-1947-5-326. ISSN 1752-1947.
↑ Kasper B, Ströbel P, Hohenberger P (2011). “Desmoid tumors: clinical features and treatment options for advanced disease”. Oncologist. 16 (5): 682–93. doi:10.1634/theoncologist.2010-0281. PMC 3228186. PMID 21478276.
↑ Carlson JW, Fletcher CD (2007). “Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature”. Histopathology. 51 (4): 509–14. doi:10.1111/j.1365-2559.2007.02794.x. PMID 17711447.
↑ ^4.0 ^4.1 Wu X, Petrovic V, Torode IP, Chow CW (2009). “Low grade fibromyxoid sarcoma: problems in the diagnosis and management of a malignant tumour with bland histological appearance”. Pathology. 41 (2): 155–60. doi:10.1080/00313020802579276. PMID 19152188.
↑ ^5.0 ^5.1 Bartuma H, Möller E, Collin A, Domanski HA, Von Steyern FV, Mandahl N; et al. (2010). “Fusion of the FUS and CREB3L2 genes in a supernumerary ring chromosome in low-grade fibromyxoid sarcoma”. Cancer Genet Cytogenet. 199 (2): 143–6. doi:10.1016/j.cancergencyto.2010.02.011. PMID 20471519.
↑ ^6.0 ^6.1 Wehrli BM, Weiss SW, Yandow S, Coffin CM (2001). “Gardner-associated fibromas (GAF) in young patients: a distinct fibrous lesion that identifies unsuspected Gardner syndrome and risk for fibromatosis”. Am J Surg Pathol. 25 (5): 645–51. PMID 11342777.
↑ ^7.0 ^7.1 Coffin CM, Hornick JL, Fletcher CD (2007). “Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases”. Am J Surg Pathol. 31 (4): 509–20. doi:10.1097/01.pas.0000213393.57322.c7. PMID 17414097.
↑ Swartz RD (2009). “Idiopathic retroperitoneal fibrosis: a review of the pathogenesis and approaches to treatment”. Am J Kidney Dis. 54 (3): 546–53. doi:10.1053/j.ajkd.2009.04.019. PMID 19515472.
↑ Doyle LA, Möller E, Dal Cin P, Fletcher CD, Mertens F, Hornick JL (2011). “MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma”. Am J Surg Pathol. 35 (5): 733–41. doi:10.1097/PAS.0b013e318210c268. PMID 21415703.
↑ Lee AF, Yip S, Smith AC, Hayes MM, Nielsen TO, O’Connell JX (2011). “Low-grade fibromyxoid sarcoma of the perineum with heterotopic ossification: case report and review of the literature”. Hum Pathol. 42 (11): 1804–9. doi:10.1016/j.humpath.2011.01.023. PMID 21658743.
↑ Brasanac D, Dzelatovic NS, Stojanovic M (2013). “Giant cystic superficial low-grade fibromyxoid sarcoma”. Ann Diagn Pathol. 17 (2): 222–5. doi:10.1016/j.anndiagpath.2011.09.001. PMID 22136982.
↑ Vernon SE, Bejarano PA (2006). “Low-grade fibromyxoid sarcoma: a brief review”. Arch Pathol Lab Med. 130 (9): 1358–60. doi:10.1043/1543-2165(2006)130[1358:LFSABR]2.0.CO;2. PMID 16948525.
↑ Lane KL, Shannon RJ, Weiss SW (1997). “Hyalinizing spindle cell tumor with giant rosettes: a distinctive tumor closely resembling low-grade fibromyxoid sarcoma”. Am J Surg Pathol. 21 (12): 1481–8. PMID 9414192.
↑ Nielsen GP, Selig MK, O’Connell JX, Keel SB, Dickersin GR, Rosenberg AE (1999). “Hyalinizing spindle cell tumor with giant rosettes: a report of three cases with ultrastructural analysis”. Am J Surg Pathol. 23 (10): 1227–32. PMID 10524523.
↑ Hanau CA, Miettinen M (1995). “Solitary fibrous tumor: histological and immunohistochemical spectrum of benign and malignant variants presenting at different sites”. Hum Pathol. 26 (4): 440–9. PMID 7705824.
↑ de Saint Aubain Somerhausen N, Rubin BP, Fletcher CD (1999). “Myxoid solitary fibrous tumor: a study of seven cases with emphasis on differential diagnosis”. Mod Pathol. 12 (5): 463–71. PMID 10349983.
↑ Cranshaw IM, Gikas PD, Fisher C, Thway K, Thomas JM, Hayes AJ (2009). “Clinical outcomes of extra-thoracic solitary fibrous tumours”. Eur J Surg Oncol. 35 (9): 994–8. doi:10.1016/j.ejso.2009.02.015. PMID 19345055.
↑ England DM, Hochholzer L, McCarthy MJ (1989). “Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases”. Am J Surg Pathol. 13 (8): 640–58. PMID 2665534.
↑ Demicco EG, Park MS, Araujo DM, Fox PS, Bassett RL, Pollock RE; et al. (2012). “Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model”. Mod Pathol. 25 (9): 1298–306. doi:10.1038/modpathol.2012.83. PMID 22575866.
↑ van Houdt WJ, Westerveld CM, Vrijenhoek JE, van Gorp J, van Coevorden F, Verhoef C; et al. (2013). “Prognosis of solitary fibrous tumors: a multicenter study”. Ann Surg Oncol. 20 (13): 4090–5. doi:10.1245/s10434-013-3242-9. PMID 24052313.
↑ Chmielecki J, Crago AM, Rosenberg M, O’Connor R, Walker SR, Ambrogio L; et al. (2013). “Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors”. Nat Genet. 45 (2): 131–2. doi:10.1038/ng.2522. PMC 3984043. PMID 23313954.
↑ Robinson DR, Wu YM, Kalyana-Sundaram S, Cao X, Lonigro RJ, Sung YS; et al. (2013). “Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing”. Nat Genet. 45 (2): 180–5. doi:10.1038/ng.2509. PMC 3654808. PMID 23313952.
↑ Schweizer L, Koelsche C, Sahm F, Piro RM, Capper D, Reuss DE; et al. (2013). “Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein”. Acta Neuropathol. 125 (5): 651–8. doi:10.1007/s00401-013-1117-6. PMID 23575898.
↑ Coffin, Cheryl M.; Hornick, Jason L.; Zhou, Holly; Fletcher, Christopher D.M. (2007). “Gardner Fibroma: A Clinicopathologic and Immunohistochemical Analysis of 45 Patients With 57 Fibromas”. The American Journal of Surgical Pathology. 31 (3): 410–416. doi:10.1097/01.pas.0000213348.65014.0a. ISSN 0147-5185.
↑ Dahl, Nathan A.; Sheil, Amy; Knapke, Sarah; Geller, James I. (2016). “Gardner Fibroma”. Journal of Pediatric Hematology/Oncology. 38 (5): e154–e157. doi:10.1097/MPH.0000000000000493. ISSN 1077-4114.
↑ Schäfer M, Kadmon M, Schmidt W, Treiber I, Moog U, Sutter C; et al. (2016). “Neonatal Gardner Fibroma Leads to Detection of Familial Adenomatous Polyposis: Two Case Reports”. European J Pediatr Surg Rep. 4 (1): 17–21. doi:10.1055/s-0036-1582443. PMC 5177561. PMID 28018803.
↑ Zarkavelis G, Petrakis D, Pavlidis N (2015). “Gastrointestinal stromal tumors during pregnancy: a systematic review of an uncommon but treatable malignancy”. Clin Transl Oncol. 17 (10): 757–62. doi:10.1007/s12094-015-1315-x. PMID 26055339.
↑ Navarrete A, Momblán D, Almenara R, Lacy A (2017). “Giant Gastric Gastrointestinal Stromal Tumor (GIST)”. J Gastrointest Surg. 21 (1): 202–204. doi:10.1007/s11605-016-3196-x. PMID 27384431.
↑ Scherjon S, Lam WF, Gelderblom H, Jansen FW (2009). “Gastrointestinal stromal tumor in pregnancy: a case report”. Case Rep Med. 2009: 456402. doi:10.1155/2009/456402. PMC 2745024. PMID 19763238.
↑ Acín-Gándara D, Pereira-Pérez F, Castaño-Pascual A, Durán-Poveda M, Antequera-Pérez A, Miliani-Molina C (2012). “Gastrointestinal stromal tumors: diagnosis and treatment”. Cir Cir. 80 (1): 44–51. PMID 22472152.
↑ Lanzafame S, Minutolo V, Caltabiano R, Minutolo O, Marino B, Gagliano G; et al. (2006). “About a case of GIST occurring during pregnancy with immunohistochemical expression of epidermal growth factor receptor and progesterone receptor”. Pathol Res Pract. 202 (2): 119–23. doi:10.1016/j.prp.2005.08.013. PMID 16413690.
↑ Coffin CM, Watterson J, Priest JR, Dehner LP (1995). “Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases”. Am J Surg Pathol. 19 (8): 859–72. PMID 7611533.
↑ ^33.0 ^33.1 Wenig BM, Devaney K, Bisceglia M (1995). “Inflammatory myofibroblastic tumor of the larynx. A clinicopathologic study of eight cases simulating a malignant spindle cell neoplasm”. Cancer. 76 (11): 2217–29. PMID 8635024.
↑ Ramachandra S, Hollowood K, Bisceglia M, Fletcher CD (1995). “Inflammatory pseudotumour of soft tissues: a clinicopathological and immunohistochemical analysis of 18 cases”. Histopathology. 27 (4): 313–23. PMID 8847061.
↑ Häusler M, Schaade L, Ramaekers VT, Doenges M, Heimann G, Sellhaus B (2003). “Inflammatory pseudotumors of the central nervous system: report of 3 cases and a literature review”. Hum Pathol. 34 (3): 253–62. doi:10.1053/hupa.2003.35. PMID 12673560.
↑ ^36.0 ^36.1 Rabban JT, Zaloudek CJ, Shekitka KM, Tavassoli FA (2005). “Inflammatory myofibroblastic tumor of the uterus: a clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors”. Am J Surg Pathol. 29 (10): 1348–55. PMID 16160478.
↑ Kovach SJ, Fischer AC, Katzman PJ, Salloum RM, Ettinghausen SE, Madeb R; et al. (2006). “Inflammatory myofibroblastic tumors”. J Surg Oncol. 94 (5): 385–91. doi:10.1002/jso.20516. PMID 16967468.
↑ Coffin CM, Dehner LP, Meis-Kindblom JM (1998). “Inflammatory myofibroblastic tumor, inflammatory fibrosarcoma, and related lesions: an historical review with differential diagnostic considerations”. Semin Diagn Pathol. 15 (2): 102–10. PMID 9606802.
↑ Berardi RS, Lee SS, Chen HP, Stines GJ (1983). “Inflammatory pseudotumors of the lung”. Surg Gynecol Obstet. 156 (1): 89–96. PMID 6336632.
↑ Durst AL, Freund H, Rosenmann E, Birnbaum D (1977). “Mesenteric panniculitis: review of the leterature and presentation of cases”. Surgery. 81 (2): 203–11. PMID 835091.
↑ Kipfer RE, Moertel CG, Dahlin DC (1974). “Mesenteric lipodystrophy”. Ann Intern Med. 80 (5): 582–8. PMID 4499963.
↑ Monahan DW, Poston WK, Brown GJ (1989). “Mesenteric panniculitis”. South Med J. 82 (6): 782–4. PMID 2660295.
↑ Parra-Davila E, McKenney MG, Sleeman D, Hartmann R, Rao RK, McKenney K; et al. (1998). “Mesenteric panniculitis: case report and literature review”. Am Surg. 64 (8): 768–71. PMID 9697910.
↑ Kelly JK, Hwang WS (1989). “Idiopathic retractile (sclerosing) mesenteritis and its differential diagnosis”. Am J Surg Pathol. 13 (6): 513–21. PMID 2658633.
↑ Emory TS, Monihan JM, Carr NJ, Sobin LH (1997). “Sclerosing mesenteritis, mesenteric panniculitis and mesenteric lipodystrophy: a single entity?”. Am J Surg Pathol. 21 (4): 392–8. PMID 9130985.
↑ OGDEN WW, BRADBURN DM, RIVES JD (1965). “MESENTERIC PANNICULITIS: REVIEW OF 27 CASES”. Ann Surg. 161: 864–75. PMC 1409094. PMID 14295938.
↑ Khachaturian T, Hughes J (1988). “Mesenteric panniculitis”. West J Med. 148 (6): 700–1. PMC 1026221. PMID 3176478.
↑ Daskalogiannaki M, Voloudaki A, Prassopoulos P, Magkanas E, Stefanaki K, Apostolaki E; et al. (2000). “CT evaluation of mesenteric panniculitis: prevalence and associated diseases”. AJR Am J Roentgenol. 174 (2): 427–31. doi:10.2214/ajr.174.2.1740427. PMID 10658720.
↑ Akram S, Pardi DS, Schaffner JA, Smyrk TC (2007). “Sclerosing mesenteritis: clinical features, treatment, and outcome in ninety-two patients”. Clin Gastroenterol Hepatol. 5 (5): 589–96, quiz 523-4. doi:10.1016/j.cgh.2007.02.032. PMID 17478346.
↑ Sharma P, Yadav S, Needham CM, Feuerstadt P (2017). “Sclerosing mesenteritis: a systematic review of 192 cases”. Clin J Gastroenterol. 10 (2): 103–111. doi:10.1007/s12328-017-0716-5. PMID 28197781.
↑ van der Hulst RW, Rauws EA, Tytgat GN (1995). “Mesenteritis secondary to the use of a pneumatic jackhammer”. Eur J Gastroenterol Hepatol. 7 (6): 573–5. PMID 7552643.
↑ Mathew J, McKenna F, Mason J, Haboubi NY, Borghol M (2004). “Sclerosing mesenteritis with occult ileal perforation: report of a case simulating extensive intra-abdominal malignancy”. Dis Colon Rectum. 47 (11): 1974–7. PMID 15622594.
↑ Horton KM, Lawler LP, Fishman EK (2003). “CT findings in sclerosing mesenteritis (panniculitis): spectrum of disease”. Radiographics. 23 (6): 1561–7. doi:10.1148/rg.1103035010. PMID 14615565.
↑ Papadaki HA, Kouroumalis EA, Stefanaki K, Roussomoustakaki M, Daskalogiannaki ME, Reppa D; et al. (2000). “Retractile mesenteritis presenting as fever of unknown origin and autoimmune haemolytic anaemia”. Digestion. 61 (2): 145–8. doi:10.1159/000007748. PMID 10705180.
↑ Vidarsson B, Matthíasson P, Agnarsson BA, Onundarson PT (2002). “Mesenteric panniculitis presenting with autoimmune haemolytic anaemia”. Acta Haematol. 107 (1): 35–7. doi:10.1159/000046627. PMID 11818670.
↑ Vernace MA, Bellucci AG, Mossey RT, Susin M, Mailloux LU, Wilkes BM; et al. (1996). “Minimal change nephropathy associated with sclerosing mesenteritis”. Nephron. 73 (3): 473–6. doi:10.1159/000189113. PMID 8832610.
↑ Dor AM, Kohler JL, Aubrespy P, Scheiner C, Pizzi M, Lebreuil G (1982). “[Mesenteric panniculitis, an unusual initial stage of acute lupus erythematosus in a ten-year old girl (author’s transl)]”. Arch Anat Cytol Pathol. 30 (2): 121–4. PMID 7103574.
↑ Sauvaget F, Piette JC, Galezowski N, Jouanique C, Chapelon C, Blétry O; et al. (1993). “[Relapsing polychondritis and mesenteric panniculitis: apropos of 2 cases]”. Rev Med Interne. 14 (4): 253–6. PMID 8378657.
↑ Arroyo-Ávila M, Vilá LM (2014). “Limited systemic sclerosis initially presenting with mesenteric panniculitis”. BMJ Case Rep. 2014. doi:10.1136/bcr-2014-206961. PMC 4202032. PMID 25326572.
↑ Garrido A, Verdejo C, Márquez JL, Giráldez A, Trigo C, Belda O (2008). “[Intestinal lymphoma and mesenteric panniculitis: complications of undiagnosed celiac disease]”. Gastroenterol Hepatol. 31 (4): 221–4. PMID 18405487.
↑ Vaglio, A.; Maritati, F. (2016). “Idiopathic Retroperitoneal Fibrosis”. Journal of the American Society of Nephrology. 27 (7): 1880–1889. doi:10.1681/ASN.2015101110. ISSN 1046-6673.
↑ Vaglio A, Salvarani C, Buzio C (2006). “Retroperitoneal fibrosis”. Lancet. 367 (9506): 241–51. doi:10.1016/S0140-6736(06)68035-5. PMID 16427494.
↑ ORMOND JK (1948). “Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process”. J Urol. 59 (6): 1072–9. PMID 18858051.
↑ van Bommel EF (2002). “Retroperitoneal fibrosis”. Neth J Med. 60 (6): 231–42. PMID 12365466.
↑ Scheel PJ, Feeley N (2009). “Retroperitoneal fibrosis: the clinical, laboratory, and radiographic presentation”. Medicine (Baltimore). 88 (4): 202–7. doi:10.1097/MD.0b013e3181afc439. PMID 19593224.
↑ Vaglio A, Palmisano A, Alberici F, Maggiore U, Ferretti S, Cobelli R; et al. (2011). “Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial”. Lancet. 378 (9788): 338–46. doi:10.1016/S0140-6736(11)60934-3. PMID 21733570.
↑ Palmisano A, Urban ML, Corradi D, Cobelli R, Alberici F, Maritati F; et al. (2015). “Chronic periaortitis with thoracic aorta and epiaortic artery involvement: a systemic large vessel vasculitis?”. Rheumatology (Oxford). 54 (11): 2004–9. doi:10.1093/rheumatology/kev225. PMID 26106209.
↑ Uibu T, Oksa P, Auvinen A, Honkanen E, Metsärinne K, Saha H; et al. (2004). “Asbestos exposure as a risk factor for retroperitoneal fibrosis”. Lancet. 363 (9419): 1422–6. doi:10.1016/S0140-6736(04)16100-X. PMID 15121404.
↑ Koep L, Zuidema GD (1977). “The clinical significance of retroperitoneal fibrosis”. Surgery. 81 (3): 250–7. PMID 841463.
↑ Graham JR, Suby HI, LeCompte PR, Sadowsky NL (1966). “Fibrotic disorders associated with methysergide therapy for headache”. N Engl J Med. 274 (7): 359–68. doi:10.1056/NEJM196602172740701. PMID 5903120.
↑ UTZ DC, ROOKE ED, SPITTELL JA, BARTHOLOMEW LG (1965). “RETROPERITONEAL FIBROSIS IN PATIENTS TAKING METHYSERGIDE”. JAMA. 191: 983–5. PMID 14257741.
↑ Goenka AH, Shah SN, Remer EM (2012). “Imaging of the retroperitoneum”. Radiol Clin North Am. 50 (2): 333–55, vii. doi:10.1016/j.rcl.2012.02.004. PMID 22498446.
↑ Goldoni M, Bonini S, Urban ML, Palmisano A, De Palma G, Galletti E; et al. (2014). “Asbestos and smoking as risk factors for idiopathic retroperitoneal fibrosis: a case-control study”. Ann Intern Med. 161 (3): 181–8. doi:10.7326/M13-2648. PMID 25089862.
↑ H. M. Maurer, M. Beltangady, E. A. Gehan, W. Crist, D. Hammond, D. M. Hays, R. Heyn, W. Lawrence, W. Newton & J. Ortega (1988). “The Intergroup Rhabdomyosarcoma Study-I. A final report”. Cancer. 61 (2): 209–220. PMID 3275486. Unknown parameter |month= ignored (help)
↑ H. M. Maurer, E. A. Gehan, M. Beltangady, W. Crist, P. S. Dickman, S. S. Donaldson, C. Fryer, D. Hammond, D. M. Hays & J. Herrmann (1993). “The Intergroup Rhabdomyosarcoma Study-II”. Cancer. 71 (5): 1904–1922. PMID 8448756. Unknown parameter |month= ignored (help)
↑ W. Crist, E. A. Gehan, A. H. Ragab, P. S. Dickman, S. S. Donaldson, C. Fryer, D. Hammond, D. M. Hays, J. Herrmann & R. Heyn (1995). “The Third Intergroup Rhabdomyosarcoma Study”. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 13 (3): 610–630. doi:10.1200/JCO.1995.13.3.610. PMID 7884423. Unknown parameter |month= ignored (help)
↑ Michael C. G. Stevens, Annie Rey, Nathalie Bouvet, Caroline Ellershaw, Francoise Flamant, Jean Louis Habrand, H. Basil Marsden, Helene Martelli, Jose Sanchez de Toledo, Richard D. Spicer, David Spooner, Marie Jose Terrier-Lacombe, Adrian van Unnik & Odile Oberlin (2005). “Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology–SIOP Malignant Mesenchymal Tumor 89”. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23 (12): 2618–2628. doi:10.1200/JCO.2005.08.130. PMID 15728225. Unknown parameter |month= ignored (help)
↑ S. R. Months & R. B. Raney (1986). “Rhabdomyosarcoma of the head and neck in children: the experience at the Children’s Hospital of Philadelphia”. Medical and pediatric oncology. 14 (5): 288–292. PMID 3784981.
↑ J. Hicks & C. Flaitz (2002). “Rhabdomyosarcoma of the head and neck in children”. Oral oncology. 38 (5): 450–459. PMID 12110339. Unknown parameter |month= ignored (help)
↑ E. Shapiro & D. Strother (1992). “Pediatric genitourinary rhabdomyosarcoma”. The Journal of urology. 148 (6): 1761–1768. PMID 1433603. Unknown parameter |month= ignored (help)
↑ W. Jr Lawrence, D. M. Hays & T. E. Moon (1977). “Lymphatic metastasis with childhood rhabdomyosarcoma”. Cancer. 39 (2): 556–559. PMID 837339. Unknown parameter |month= ignored (help)
↑ W. Jr Lawrence, E. A. Gehan, D. M. Hays, M. Beltangady & H. M. Maurer (1987). “Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II)”. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 5 (1): 46–54. doi:10.1200/JCO.1987.5.1.46. PMID 3543238. Unknown parameter |month= ignored (help)
↑ E. S. Wiener, J. R. Anderson, J. I. Ojimba, T. E. Lobe, C. Paidas, R. J. Andrassy, R. B. Raney, S. J. Qualman, S. S. Donaldson, H. M. Maurer, M. P. Link, W. M. Crist & H. E. Grier (2001). “Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma?”. Seminars in pediatric surgery. 10 (3): 146–152. PMID 11481652. Unknown parameter |month= ignored (help)
↑ Khin Thway, Rashpal Flora, Chirag Shah, David Olmos & Cyril Fisher (2012). “Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors”. The American journal of surgical pathology. 36 (3): 462–469. doi:10.1097/PAS.0b013e3182417330. PMID 22301498. Unknown parameter |month= ignored (help)
↑ J. Rosai, M. Akerman, P. Dal Cin, I. DeWever, C. D. Fletcher, N. Mandahl, F. Mertens, F. Mitelman, A. Rydholm, R. Sciot, G. Tallini, H. Van den Berghe, W. Van de Ven, R. Vanni & H. Willen (1996). “Combined morphologic and karyotypic study of 59 atypical lipomatous tumors. Evaluation of their relationship and differential diagnosis with other adipose tissue tumors (a report of the CHAMP Study Group)”. The American journal of surgical pathology. 20 (10): 1182–1189. PMID 8827023. Unknown parameter |month= ignored (help)
↑ Dal Cin, Paola; Kools, Patrick; Sciot, Raf; De Wever, Ivo; Van Damme, Boudewijn; Van de Ven, Wim; Van Den Berghe, Herman (1993). “Cytogenetic and fluorescence in situ hybridization investigation of ring chromosomes characterizing a specific pathologic subgroup of adipose tissue tumors”. Cancer Genetics and Cytogenetics. 68 (2): 85–90. doi:10.1016/0165-4608(93)90001-3. ISSN 0165-4608.
↑ Dei Tos, Angelo P.; Doglioni, Claudio; Piccinin, Sara; Sciot, Raf; Furlanetto, Alberto; Boiocchi, Mauro; Dal Cin, Paola; Maestro, Roberta; Fletcher, Christopher D. M.; Tallini, Giovanni (2000). “Coordinated expression and amplification of theMDM2,CDK4, andHMGI-C genes in atypical lipomatous tumours”. The Journal of Pathology. 190 (5): 531–536. doi:10.1002/(SICI)1096-9896(200004)190:5<531::AID-PATH579>3.0.CO;2-W. ISSN 0022-3417.
↑ Dei Tos, A (2000). “Liposarcoma: New entities and evolving concepts”. Annals of Diagnostic Pathology. 4 (4): 252–266. doi:10.1053/adpa.2000.8133. ISSN 1092-9134.
↑ M. D. Kraus, L. Guillou & C. D. Fletcher (1997). “Well-differentiated inflammatory liposarcoma: an uncommon and easily overlooked variant of a common sarcoma”. The American journal of surgical pathology. 21 (5): 518–527. PMID 9158675. Unknown parameter |month= ignored (help)
↑ P. Argani, F. Facchetti, G. Inghirami & J. Rosai (1997). “Lymphocyte-rich well-differentiated liposarcoma: report of nine cases”. The American journal of surgical pathology. 21 (8): 884–895. PMID 9255251. Unknown parameter |month= ignored (help)
↑ H. L. Evans (1979). “Liposarcoma: a study of 55 cases with a reassessment of its classification”. The American journal of surgical pathology. 3 (6): 507–523. PMID 534388. Unknown parameter |month= ignored (help)
↑ A. P. Dei Tos, T. Mentzel, P. L. Newman & C. D. Fletcher (1994). “Spindle cell liposarcoma, a hitherto unrecognized variant of liposarcoma. Analysis of six cases”. The American journal of surgical pathology. 18 (9): 913–921. PMID 8067512. Unknown parameter |month= ignored (help)
↑ D. C. Dahlin, K. K. Unni & T. Matsuno (1977). “Malignant (fibrous) histiocytoma of bone–fact or fancy?”. Cancer. 39 (4): 1508–1516. PMID 192432. Unknown parameter |month= ignored (help)
↑ Laura M. 3rd Arnold, Sudeep D. Burman & Albert H. O-Yurvati (2010). “Diagnosis and management of primary pulmonary leiomyosarcoma”. The Journal of the American Osteopathic Association. 110 (4): 244–246. PMID 20430913. Unknown parameter |month= ignored (help)
↑ Wilkinson, N; Rollason, T P (2001). “Recent advances in the pathology of smooth muscle tumours of the uterus”. Histopathology. 39 (4): 331–341. doi:10.1046/j.1365-2559.2001.01300.x. ISSN 0309-0167.
↑ S. W. Bell, R. L. Kempson & M. R. Hendrickson (1994). “Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases”. The American journal of surgical pathology. 18 (6): 535–558. PMID 8179071. Unknown parameter |month= ignored (help)
↑ Launonen, V.; Vierimaa, O.; Kiuru, M.; Isola, J.; Roth, S.; Pukkala, E.; Sistonen, P.; Herva, R.; Aaltonen, L. A. (2001). “Inherited susceptibility to uterine leiomyomas and renal cell cancer”. Proceedings of the National Academy of Sciences. 98 (6): 3387–3392. doi:10.1073/pnas.051633798. ISSN 0027-8424.
↑ McClain, Kenneth L.; Leach, Charles T.; Jenson, Hal B.; Joshi, Vijay V.; Pollock, Brad H.; Parmley, Richard T.; DiCarlo, Frederick J.; Chadwick, Ellen Gould; Murphy, Sharon B. (1995). “Association of Epstein–Barr Virus with Leiomyosarcomas in Young People with AIDS”. New England Journal of Medicine. 332 (1): 12–18. doi:10.1056/NEJM199501053320103. ISSN 0028-4793.
↑ Fang, Zhiwei; Matsumoto, Seiichi; Ae, Keisuke; Kawaguchi, Noriyoshi; Yoshikawa, Hideki; Ueda, Takafumi; Ishii, Takeshi; Araki, Nobuhito; Kito, Masashi (2004). “Postradiation soft tissue sarcoma: a multiinstitutional analysis of 14 cases in Japan”. Journal of Orthopaedic Science. 9 (3): 242–246. doi:10.1007/s00776-004-0768-5. ISSN 0949-2658.
↑ Futuri, S.; Donohoe, K.; Spaccavento, C.; Yudelman, I. (2014). “Rectal leiomyosarcoma: a rare and long-term complication of radiation therapy”. Case Reports. 2014 (oct14 1): bcr2014205240–bcr2014205240. doi:10.1136/bcr-2014-205240. ISSN 1757-790X.
↑ Lynch, Henry T.; Deters, Carolyn A.; Hogg, David; Lynch, Jane F.; Kinarsky, Yulia; Gatalica, Zoran (2003). “Familial sarcoma”. Cancer. 98 (9): 1947–1957. doi:10.1002/cncr.11743. ISSN 0008-543X.
↑ Yu, C.-L.; Tucker, M. A.; Abramson, D. H.; Furukawa, K.; Seddon, J. M.; Stovall, M.; Fraumeni, J. F.; Kleinerman, R. A. (2009). “Cause-Specific Mortality in Long-Term Survivors of Retinoblastoma”. JNCI Journal of the National Cancer Institute. 101 (8): 581–591. doi:10.1093/jnci/djp046. ISSN 0027-8874.
↑ Rodriguez, Fausto J.; Folpe, Andrew L.; Giannini, Caterina; Perry, Arie (2012). “Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems”. Acta Neuropathologica. 123 (3): 295–319. doi:10.1007/s00401-012-0954-z. ISSN 0001-6322.
↑ Choi, Kwangmin; Komurov, Kakajan; Fletcher, Jonathan S.; Jousma, Edwin; Cancelas, Jose A.; Wu, Jianqiang; Ratner, Nancy (2017). “An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system”. Scientific Reports. 7 (1). doi:10.1038/srep43315. ISSN 2045-2322.
↑ Liao, Chung-Ping; Booker, Reid C.; Brosseau, Jean-Philippe; Chen, Zhiguo; Mo, Juan; Tchegnon, Edem; Wang, Yong; Clapp, D. Wade; Le, Lu Q. (2018). “Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis”. Journal of Clinical Investigation. 128 (7): 2848–2861. doi:10.1172/JCI99424. ISSN 0021-9738.
↑ ^106.0 ^106.1 Staser, K.; Yang, F.-C.; Clapp, D. W. (2010). “Mast cells and the neurofibroma microenvironment”. Blood. 116 (2): 157–164. doi:10.1182/blood-2009-09-242875. ISSN 0006-4971.
↑ Muir, David; Neubauer, Debbie; Lim, Ingrid T.; Yachnis, Anthony T.; Wallace, Margaret R. (2001). “Tumorigenic Properties of Neurofibromin-Deficient Neurofibroma Schwann Cells”. The American Journal of Pathology. 158 (2): 501–513. doi:10.1016/S0002-9440(10)63992-2. ISSN 0002-9440.
↑ Wilkinson, Lana M.; Manson, David; Smith, Charles R. (2004). “Best Cases from the AFIP”. RadioGraphics. 24 (suppl_1): S237–S242. doi:10.1148/rg.24si035170. ISSN 0271-5333.
↑ Bernthal, Nicholas; Jones, Kevin; Monument, Michael; Liu, Ting; Viskochil, David; Randall, R. (2013). “Lost in Translation: Ambiguity in Nerve Sheath Tumor Nomenclature and Its Resultant Treatment Effect”. Cancers. 5 (4): 519–528. doi:10.3390/cancers5020519. ISSN 2072-6694.
↑ Mautner, V. F.; Friedrich, R. E.; von Deimling, A.; Hagel, C.; Korf, B.; Knöfel, M. T.; Wenzel, R.; Fünsterer, C. (2003). “Malignant peripheral nerve sheath tumours in neurofibromatosis type 1: MRI supports the diagnosis of malignant plexiform neurofibroma”. Neuroradiology. 45 (9): 618–625. doi:10.1007/s00234-003-0964-6. ISSN 0028-3940.
↑ Shen, M H; Harper, P S; Upadhyaya, M (1996). “Molecular genetics of neurofibromatosis type 1 (NF1)”. Journal of Medical Genetics. 33 (1): 2–17. doi:10.1136/jmg.33.1.2. ISSN 1468-6244.
↑ Rubin, Joshua B.; Gutmann, David H. (2005). “Neurofibromatosis type 1 — a model for nervous system tumour formation?”. Nature Reviews Cancer. 5 (7): 557–564. doi:10.1038/nrc1653. ISSN 1474-175X.
↑ Sailon AM, Cappuccino G, Hameed M, Fleegler EJ (2008). “Nodular fasciitis of the hand over the metacarpophalangeal joint: a case report”. Eplasty. 8: e38. PMC 2491338. PMID 18725954.
↑ Emori, M; Shimizu, J; Murahashi, Y; Mizushima, E; Sugita, S; Hasegawa, T; Yamashita, T (2018). “Nodular fasciitis involving the palm”. The Annals of The Royal College of Surgeons of England. 100 (5): e128–e131. doi:10.1308/rcsann.2018.0061. ISSN 0035-8843.
↑ Kubota, Kensuke; Okada, Seiji; Maeda, Takeshi; Matsumoto, Yoshihiro; Sakamoto, Akio; Harimaya, Katsumi; Saiwai, Hirokazu; Kumamaru, Hiromi; Oda, Yoshinao; Iwamoto, Yukihide (2012). “Extradural Nodular Fasciitis Arising in the Spinal Canal”. Spine. 37 (2): E133–E137. doi:10.1097/BRS.0b013e318224568a. ISSN 0362-2436.
↑ Plaza JA, Mayerson J, Wakely PE (2005). “Nodular fasciitis of the hand: a potential diagnostic pitfall in fine-needle aspiration cytopathology”. Am J Clin Pathol. 123 (3): 388–93. doi:10.1309/PWD0-HB51-1L3V-R56W. PMID 15716235.
↑ Wagner LM, Gelfand MJ, Laor T, Ryckman FC, Al-Ghawi H, Bove KE (2011). “A welcome surprise: nodular fasciitis presenting as soft tissue sarcoma”. J Pediatr Hematol Oncol. 33 (4): 316–9. doi:10.1097/MPH.0b013e3181e88649. PMID 20975584.
↑ Grobmyer SR, Knapik JA, Foss RM, Copeland EM, Hochwald SN (2009). “Nodular fasciitis: differential considerations and current management strategies”. Am Surg. 75 (7): 610–4. PMID 19655607.
↑ Yamamoto H, Yamada N, Yamada I, Hashikawa K, Kagimoto K, Ookubo M; et al. (1998). “[A case of nodular fasciitis of the chest wall]”. Kyobu Geka. 51 (3): 246–9. PMID 9528235.
↑ Chiarini L, Lo Russo L, Figurelli S, Procacci P, Rubini C, Lo Muzio L (2008). “Nodular fasciitis of the face: aesthetic considerations”. Aesthetic Plast Surg. 32 (3): 560–2. doi:10.1007/s00266-008-9136-8. PMID 18330617.
↑ Oliveira AM, Chou MM (2014). “USP6-induced neoplasms: the biologic spectrum of aneurysmal bone cyst and nodular fasciitis”. Hum Pathol. 45 (1): 1–11. doi:10.1016/j.humpath.2013.03.005. PMID 23769422.
↑ Erickson-Johnson MR, Chou MM, Evers BR, Roth CW, Seys AR, Jin L; et al. (2011). “Nodular fasciitis: a novel model of transient neoplasia induced by MYH9-USP6 gene fusion”. Lab Invest. 91 (10): 1427–33. doi:10.1038/labinvest.2011.118. PMID 21826056.
↑ . doi:10.4197/Med. 17-3.1 Check |doi= value (help). Missing or empty |title= (help)
↑ Russell SB, Russell JD, Trupin KM, Gayden AE, Opalenik SR, Nanney LB; et al. (2010). “Epigenetically altered wound healing in keloid fibroblasts”. J Invest Dermatol. 130 (10): 2489–96. doi:10.1038/jid.2010.162. PMC 2939920. PMID 20555348.
↑ Smith JC, Boone BE, Opalenik SR, Williams SM, Russell SB (2008). “Gene profiling of keloid fibroblasts shows altered expression in multiple fibrosis-associated pathways”. J Invest Dermatol. 128 (5): 1298–310. doi:10.1038/sj.jid.5701149. PMC 2933038. PMID 17989729.
↑ Huang, Chenyu; Murphy, George F.; Akaishi, Satoshi; Ogawa, Rei (2013). “Keloids and Hypertrophic Scars”. Plastic and Reconstructive Surgery Global Open. 1 (4): e25. doi:10.1097/GOX.0b013e31829c4597. ISSN 2169-7574.
↑ Smoll NR (2012). “Relative survival of childhood and adult medulloblastomas and primitive neuroectodermal tumors (PNETs)”. Cancer. 118 (5): 1313–22. doi:10.1002/cncr.26387. PMID 21837678.
↑ Eibl RH, Kleihues P, Jat PS, Wiestler OD (1994). “A model for primitive neuroectodermal tumors in transgenic neural transplants harboring the SV40 large T antigen”. Am J Pathol. 144 (3): 556–64. PMC 1887088. PMID 8129041.
↑ Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P (1991). “p53 mutations in nonastrocytic human brain tumors”. Cancer Res. 51 (22): 6202–5. PMID 1933879.

Template:WikiDoc Sources

[EconomouPitta2011-1] Economou, Athanasios; Pitta, Xanthi; Andreadis, Efstathios; Papapavlou, Leonidas; Chrissidis, Thomas (2011). “Desmoid tumor of the abdominal wall: a case report”. Journal of Medical Case Reports. 5 (1): 326. doi:10.1186/1752-1947-5-326. ISSN 1752-1947.

[pmid21478276-2] Kasper B, Ströbel P, Hohenberger P (2011). “Desmoid tumors: clinical features and treatment options for advanced disease”. Oncologist. 16 (5): 682–93. doi:10.1634/theoncologist.2010-0281. PMC 3228186. PMID 21478276.

[pmid17711447-3] Carlson JW, Fletcher CD (2007). “Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature”. Histopathology. 51 (4): 509–14. doi:10.1111/j.1365-2559.2007.02794.x. PMID 17711447.

[pmid19152188-4] 4.0 ^4.1 Wu X, Petrovic V, Torode IP, Chow CW (2009). “Low grade fibromyxoid sarcoma: problems in the diagnosis and management of a malignant tumour with bland histological appearance”. Pathology. 41 (2): 155–60. doi:10.1080/00313020802579276. PMID 19152188.

[pmid20471519-5] 5.0 ^5.1 Bartuma H, Möller E, Collin A, Domanski HA, Von Steyern FV, Mandahl N; et al. (2010). “Fusion of the FUS and CREB3L2 genes in a supernumerary ring chromosome in low-grade fibromyxoid sarcoma”. Cancer Genet Cytogenet. 199 (2): 143–6. doi:10.1016/j.cancergencyto.2010.02.011. PMID 20471519.

[pmid11342777-6] 6.0 ^6.1 Wehrli BM, Weiss SW, Yandow S, Coffin CM (2001). “Gardner-associated fibromas (GAF) in young patients: a distinct fibrous lesion that identifies unsuspected Gardner syndrome and risk for fibromatosis”. Am J Surg Pathol. 25 (5): 645–51. PMID 11342777.

[pmid17414097-7] 7.0 ^7.1 Coffin CM, Hornick JL, Fletcher CD (2007). “Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases”. Am J Surg Pathol. 31 (4): 509–20. doi:10.1097/01.pas.0000213393.57322.c7. PMID 17414097.

[pmid19515472-8] Swartz RD (2009). “Idiopathic retroperitoneal fibrosis: a review of the pathogenesis and approaches to treatment”. Am J Kidney Dis. 54 (3): 546–53. doi:10.1053/j.ajkd.2009.04.019. PMID 19515472.

[pmid21415703-9] Doyle LA, Möller E, Dal Cin P, Fletcher CD, Mertens F, Hornick JL (2011). “MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma”. Am J Surg Pathol. 35 (5): 733–41. doi:10.1097/PAS.0b013e318210c268. PMID 21415703.

[pmid21658743-10] Lee AF, Yip S, Smith AC, Hayes MM, Nielsen TO, O’Connell JX (2011). “Low-grade fibromyxoid sarcoma of the perineum with heterotopic ossification: case report and review of the literature”. Hum Pathol. 42 (11): 1804–9. doi:10.1016/j.humpath.2011.01.023. PMID 21658743.

[pmid22136982-11] Brasanac D, Dzelatovic NS, Stojanovic M (2013). “Giant cystic superficial low-grade fibromyxoid sarcoma”. Ann Diagn Pathol. 17 (2): 222–5. doi:10.1016/j.anndiagpath.2011.09.001. PMID 22136982.

[pmid16948525-12] Vernon SE, Bejarano PA (2006). “Low-grade fibromyxoid sarcoma: a brief review”. Arch Pathol Lab Med. 130 (9): 1358–60. doi:10.1043/1543-2165(2006)130[1358:LFSABR]2.0.CO;2. PMID 16948525.

[pmid9414192-13] Lane KL, Shannon RJ, Weiss SW (1997). “Hyalinizing spindle cell tumor with giant rosettes: a distinctive tumor closely resembling low-grade fibromyxoid sarcoma”. Am J Surg Pathol. 21 (12): 1481–8. PMID 9414192.

[pmid10524523-14] Nielsen GP, Selig MK, O’Connell JX, Keel SB, Dickersin GR, Rosenberg AE (1999). “Hyalinizing spindle cell tumor with giant rosettes: a report of three cases with ultrastructural analysis”. Am J Surg Pathol. 23 (10): 1227–32. PMID 10524523.

[pmid7705824-15] Hanau CA, Miettinen M (1995). “Solitary fibrous tumor: histological and immunohistochemical spectrum of benign and malignant variants presenting at different sites”. Hum Pathol. 26 (4): 440–9. PMID 7705824.

[pmid10349983-16] Saint Aubain Somerhausen N, Rubin BP, Fletcher CD (1999). “Myxoid solitary fibrous tumor: a study of seven cases with emphasis on differential diagnosis”. Mod Pathol. 12 (5): 463–71. PMID 10349983.

[pmid19345055-17] Cranshaw IM, Gikas PD, Fisher C, Thway K, Thomas JM, Hayes AJ (2009). “Clinical outcomes of extra-thoracic solitary fibrous tumours”. Eur J Surg Oncol. 35 (9): 994–8. doi:10.1016/j.ejso.2009.02.015. PMID 19345055.

[pmid2665534-18] England DM, Hochholzer L, McCarthy MJ (1989). “Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases”. Am J Surg Pathol. 13 (8): 640–58. PMID 2665534.

[pmid22575866-19] Demicco EG, Park MS, Araujo DM, Fox PS, Bassett RL, Pollock RE; et al. (2012). “Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model”. Mod Pathol. 25 (9): 1298–306. doi:10.1038/modpathol.2012.83. PMID 22575866.

[pmid24052313-20] van Houdt WJ, Westerveld CM, Vrijenhoek JE, van Gorp J, van Coevorden F, Verhoef C; et al. (2013). “Prognosis of solitary fibrous tumors: a multicenter study”. Ann Surg Oncol. 20 (13): 4090–5. doi:10.1245/s10434-013-3242-9. PMID 24052313.

[pmid23313954-21] Chmielecki J, Crago AM, Rosenberg M, O’Connor R, Walker SR, Ambrogio L; et al. (2013). “Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors”. Nat Genet. 45 (2): 131–2. doi:10.1038/ng.2522. PMC 3984043. PMID 23313954.

[pmid23313952-22] Robinson DR, Wu YM, Kalyana-Sundaram S, Cao X, Lonigro RJ, Sung YS; et al. (2013). “Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing”. Nat Genet. 45 (2): 180–5. doi:10.1038/ng.2509. PMC 3654808. PMID 23313952.

[pmid23575898-23] Schweizer L, Koelsche C, Sahm F, Piro RM, Capper D, Reuss DE; et al. (2013). “Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein”. Acta Neuropathol. 125 (5): 651–8. doi:10.1007/s00401-013-1117-6. PMID 23575898.

[CoffinHornick2007-24] Coffin, Cheryl M.; Hornick, Jason L.; Zhou, Holly; Fletcher, Christopher D.M. (2007). “Gardner Fibroma: A Clinicopathologic and Immunohistochemical Analysis of 45 Patients With 57 Fibromas”. The American Journal of Surgical Pathology. 31 (3): 410–416. doi:10.1097/01.pas.0000213348.65014.0a. ISSN 0147-5185.

[DahlSheil2016-25] Dahl, Nathan A.; Sheil, Amy; Knapke, Sarah; Geller, James I. (2016). “Gardner Fibroma”. Journal of Pediatric Hematology/Oncology. 38 (5): e154–e157. doi:10.1097/MPH.0000000000000493. ISSN 1077-4114.

[pmid28018803-26] Schäfer M, Kadmon M, Schmidt W, Treiber I, Moog U, Sutter C; et al. (2016). “Neonatal Gardner Fibroma Leads to Detection of Familial Adenomatous Polyposis: Two Case Reports”. European J Pediatr Surg Rep. 4 (1): 17–21. doi:10.1055/s-0036-1582443. PMC 5177561. PMID 28018803.

[pmid26055339-27] Zarkavelis G, Petrakis D, Pavlidis N (2015). “Gastrointestinal stromal tumors during pregnancy: a systematic review of an uncommon but treatable malignancy”. Clin Transl Oncol. 17 (10): 757–62. doi:10.1007/s12094-015-1315-x. PMID 26055339.

[pmid27384431-28] Navarrete A, Momblán D, Almenara R, Lacy A (2017). “Giant Gastric Gastrointestinal Stromal Tumor (GIST)”. J Gastrointest Surg. 21 (1): 202–204. doi:10.1007/s11605-016-3196-x. PMID 27384431.

[pmid19763238-29] Scherjon S, Lam WF, Gelderblom H, Jansen FW (2009). “Gastrointestinal stromal tumor in pregnancy: a case report”. Case Rep Med. 2009: 456402. doi:10.1155/2009/456402. PMC 2745024. PMID 19763238.

[pmid22472152-30] Acín-Gándara D, Pereira-Pérez F, Castaño-Pascual A, Durán-Poveda M, Antequera-Pérez A, Miliani-Molina C (2012). “Gastrointestinal stromal tumors: diagnosis and treatment”. Cir Cir. 80 (1): 44–51. PMID 22472152.

[pmid16413690-31] Lanzafame S, Minutolo V, Caltabiano R, Minutolo O, Marino B, Gagliano G; et al. (2006). “About a case of GIST occurring during pregnancy with immunohistochemical expression of epidermal growth factor receptor and progesterone receptor”. Pathol Res Pract. 202 (2): 119–23. doi:10.1016/j.prp.2005.08.013. PMID 16413690.

[pmid7611533-32] Coffin CM, Watterson J, Priest JR, Dehner LP (1995). “Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases”. Am J Surg Pathol. 19 (8): 859–72. PMID 7611533.

[pmid8635024-33] 33.0 ^33.1 Wenig BM, Devaney K, Bisceglia M (1995). “Inflammatory myofibroblastic tumor of the larynx. A clinicopathologic study of eight cases simulating a malignant spindle cell neoplasm”. Cancer. 76 (11): 2217–29. PMID 8635024.

[pmid8847061-34] Ramachandra S, Hollowood K, Bisceglia M, Fletcher CD (1995). “Inflammatory pseudotumour of soft tissues: a clinicopathological and immunohistochemical analysis of 18 cases”. Histopathology. 27 (4): 313–23. PMID 8847061.

[pmid12673560-35] Häusler M, Schaade L, Ramaekers VT, Doenges M, Heimann G, Sellhaus B (2003). “Inflammatory pseudotumors of the central nervous system: report of 3 cases and a literature review”. Hum Pathol. 34 (3): 253–62. doi:10.1053/hupa.2003.35. PMID 12673560.

[pmid16160478-36] 36.0 ^36.1 Rabban JT, Zaloudek CJ, Shekitka KM, Tavassoli FA (2005). “Inflammatory myofibroblastic tumor of the uterus: a clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors”. Am J Surg Pathol. 29 (10): 1348–55. PMID 16160478.

[pmid16967468-37] Kovach SJ, Fischer AC, Katzman PJ, Salloum RM, Ettinghausen SE, Madeb R; et al. (2006). “Inflammatory myofibroblastic tumors”. J Surg Oncol. 94 (5): 385–91. doi:10.1002/jso.20516. PMID 16967468.

[pmid9606802-38] Coffin CM, Dehner LP, Meis-Kindblom JM (1998). “Inflammatory myofibroblastic tumor, inflammatory fibrosarcoma, and related lesions: an historical review with differential diagnostic considerations”. Semin Diagn Pathol. 15 (2): 102–10. PMID 9606802.

[pmid6336632-39] Berardi RS, Lee SS, Chen HP, Stines GJ (1983). “Inflammatory pseudotumors of the lung”. Surg Gynecol Obstet. 156 (1): 89–96. PMID 6336632.

[pmid835091-40] Durst AL, Freund H, Rosenmann E, Birnbaum D (1977). “Mesenteric panniculitis: review of the leterature and presentation of cases”. Surgery. 81 (2): 203–11. PMID 835091.

[pmid4499963-41] Kipfer RE, Moertel CG, Dahlin DC (1974). “Mesenteric lipodystrophy”. Ann Intern Med. 80 (5): 582–8. PMID 4499963.

[pmid2660295-42] Monahan DW, Poston WK, Brown GJ (1989). “Mesenteric panniculitis”. South Med J. 82 (6): 782–4. PMID 2660295.

[pmid9697910-43] Parra-Davila E, McKenney MG, Sleeman D, Hartmann R, Rao RK, McKenney K; et al. (1998). “Mesenteric panniculitis: case report and literature review”. Am Surg. 64 (8): 768–71. PMID 9697910.

[pmid2658633-44] Kelly JK, Hwang WS (1989). “Idiopathic retractile (sclerosing) mesenteritis and its differential diagnosis”. Am J Surg Pathol. 13 (6): 513–21. PMID 2658633.

[pmid9130985-45] Emory TS, Monihan JM, Carr NJ, Sobin LH (1997). “Sclerosing mesenteritis, mesenteric panniculitis and mesenteric lipodystrophy: a single entity?”. Am J Surg Pathol. 21 (4): 392–8. PMID 9130985.

[pmid14295938-46] OGDEN WW, BRADBURN DM, RIVES JD (1965). “MESENTERIC PANNICULITIS: REVIEW OF 27 CASES”. Ann Surg. 161: 864–75. PMC 1409094. PMID 14295938.

[pmid3176478-47] Khachaturian T, Hughes J (1988). “Mesenteric panniculitis”. West J Med. 148 (6): 700–1. PMC 1026221. PMID 3176478.

[pmid10658720-48] Daskalogiannaki M, Voloudaki A, Prassopoulos P, Magkanas E, Stefanaki K, Apostolaki E; et al. (2000). “CT evaluation of mesenteric panniculitis: prevalence and associated diseases”. AJR Am J Roentgenol. 174 (2): 427–31. doi:10.2214/ajr.174.2.1740427. PMID 10658720.

[pmid17478346-49] Akram S, Pardi DS, Schaffner JA, Smyrk TC (2007). “Sclerosing mesenteritis: clinical features, treatment, and outcome in ninety-two patients”. Clin Gastroenterol Hepatol. 5 (5): 589–96, quiz 523-4. doi:10.1016/j.cgh.2007.02.032. PMID 17478346.

[pmid28197781-50] Sharma P, Yadav S, Needham CM, Feuerstadt P (2017). “Sclerosing mesenteritis: a systematic review of 192 cases”. Clin J Gastroenterol. 10 (2): 103–111. doi:10.1007/s12328-017-0716-5. PMID 28197781.

[pmid7552643-51] van der Hulst RW, Rauws EA, Tytgat GN (1995). “Mesenteritis secondary to the use of a pneumatic jackhammer”. Eur J Gastroenterol Hepatol. 7 (6): 573–5. PMID 7552643.

[pmid15622594-52] Mathew J, McKenna F, Mason J, Haboubi NY, Borghol M (2004). “Sclerosing mesenteritis with occult ileal perforation: report of a case simulating extensive intra-abdominal malignancy”. Dis Colon Rectum. 47 (11): 1974–7. PMID 15622594.

[pmid14615565-53] Horton KM, Lawler LP, Fishman EK (2003). “CT findings in sclerosing mesenteritis (panniculitis): spectrum of disease”. Radiographics. 23 (6): 1561–7. doi:10.1148/rg.1103035010. PMID 14615565.

[pmid10705180-54] Papadaki HA, Kouroumalis EA, Stefanaki K, Roussomoustakaki M, Daskalogiannaki ME, Reppa D; et al. (2000). “Retractile mesenteritis presenting as fever of unknown origin and autoimmune haemolytic anaemia”. Digestion. 61 (2): 145–8. doi:10.1159/000007748. PMID 10705180.

[pmid11818670-55] Vidarsson B, Matthíasson P, Agnarsson BA, Onundarson PT (2002). “Mesenteric panniculitis presenting with autoimmune haemolytic anaemia”. Acta Haematol. 107 (1): 35–7. doi:10.1159/000046627. PMID 11818670.

[pmid8832610-56] Vernace MA, Bellucci AG, Mossey RT, Susin M, Mailloux LU, Wilkes BM; et al. (1996). “Minimal change nephropathy associated with sclerosing mesenteritis”. Nephron. 73 (3): 473–6. doi:10.1159/000189113. PMID 8832610.

[pmid7103574-57] Dor AM, Kohler JL, Aubrespy P, Scheiner C, Pizzi M, Lebreuil G (1982). “[Mesenteric panniculitis, an unusual initial stage of acute lupus erythematosus in a ten-year old girl (author’s transl)]”. Arch Anat Cytol Pathol. 30 (2): 121–4. PMID 7103574.

[pmid8378657-58] Sauvaget F, Piette JC, Galezowski N, Jouanique C, Chapelon C, Blétry O; et al. (1993). “[Relapsing polychondritis and mesenteric panniculitis: apropos of 2 cases]”. Rev Med Interne. 14 (4): 253–6. PMID 8378657.

[pmid25326572-59] Arroyo-Ávila M, Vilá LM (2014). “Limited systemic sclerosis initially presenting with mesenteric panniculitis”. BMJ Case Rep. 2014. doi:10.1136/bcr-2014-206961. PMC 4202032. PMID 25326572.

[pmid18405487-60] Garrido A, Verdejo C, Márquez JL, Giráldez A, Trigo C, Belda O (2008). “[Intestinal lymphoma and mesenteric panniculitis: complications of undiagnosed celiac disease]”. Gastroenterol Hepatol. 31 (4): 221–4. PMID 18405487.

[VaglioMaritati2016-61] Vaglio, A.; Maritati, F. (2016). “Idiopathic Retroperitoneal Fibrosis”. Journal of the American Society of Nephrology. 27 (7): 1880–1889. doi:10.1681/ASN.2015101110. ISSN 1046-6673.

[pmid16427494-62] Vaglio A, Salvarani C, Buzio C (2006). “Retroperitoneal fibrosis”. Lancet. 367 (9506): 241–51. doi:10.1016/S0140-6736(06)68035-5. PMID 16427494.

[pmid18858051-63] ORMOND JK (1948). “Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process”. J Urol. 59 (6): 1072–9. PMID 18858051.

[pmid12365466-64] van Bommel EF (2002). “Retroperitoneal fibrosis”. Neth J Med. 60 (6): 231–42. PMID 12365466.

[pmid19593224-65] Scheel PJ, Feeley N (2009). “Retroperitoneal fibrosis: the clinical, laboratory, and radiographic presentation”. Medicine (Baltimore). 88 (4): 202–7. doi:10.1097/MD.0b013e3181afc439. PMID 19593224.

[pmid21733570-66] Vaglio A, Palmisano A, Alberici F, Maggiore U, Ferretti S, Cobelli R; et al. (2011). “Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial”. Lancet. 378 (9788): 338–46. doi:10.1016/S0140-6736(11)60934-3. PMID 21733570.

[pmid26106209-67] Palmisano A, Urban ML, Corradi D, Cobelli R, Alberici F, Maritati F; et al. (2015). “Chronic periaortitis with thoracic aorta and epiaortic artery involvement: a systemic large vessel vasculitis?”. Rheumatology (Oxford). 54 (11): 2004–9. doi:10.1093/rheumatology/kev225. PMID 26106209.

[pmid15121404-68] Uibu T, Oksa P, Auvinen A, Honkanen E, Metsärinne K, Saha H; et al. (2004). “Asbestos exposure as a risk factor for retroperitoneal fibrosis”. Lancet. 363 (9419): 1422–6. doi:10.1016/S0140-6736(04)16100-X. PMID 15121404.

[pmid841463-69] Koep L, Zuidema GD (1977). “The clinical significance of retroperitoneal fibrosis”. Surgery. 81 (3): 250–7. PMID 841463.

[pmid5903120-70] Graham JR, Suby HI, LeCompte PR, Sadowsky NL (1966). “Fibrotic disorders associated with methysergide therapy for headache”. N Engl J Med. 274 (7): 359–68. doi:10.1056/NEJM196602172740701. PMID 5903120.

[pmid14257741-71] UTZ DC, ROOKE ED, SPITTELL JA, BARTHOLOMEW LG (1965). “RETROPERITONEAL FIBROSIS IN PATIENTS TAKING METHYSERGIDE”. JAMA. 191: 983–5. PMID 14257741.

[pmid22498446-72] Goenka AH, Shah SN, Remer EM (2012). “Imaging of the retroperitoneum”. Radiol Clin North Am. 50 (2): 333–55, vii. doi:10.1016/j.rcl.2012.02.004. PMID 22498446.

[pmid25089862-73] Goldoni M, Bonini S, Urban ML, Palmisano A, De Palma G, Galletti E; et al. (2014). “Asbestos and smoking as risk factors for idiopathic retroperitoneal fibrosis: a case-control study”. Ann Intern Med. 161 (3): 181–8. doi:10.7326/M13-2648. PMID 25089862.

[74] H. M. Maurer, M. Beltangady, E. A. Gehan, W. Crist, D. Hammond, D. M. Hays, R. Heyn, W. Lawrence, W. Newton & J. Ortega (1988). “The Intergroup Rhabdomyosarcoma Study-I. A final report”. Cancer. 61 (2): 209–220. PMID 3275486. Unknown parameter |month= ignored (help)

[75] H. M. Maurer, E. A. Gehan, M. Beltangady, W. Crist, P. S. Dickman, S. S. Donaldson, C. Fryer, D. Hammond, D. M. Hays & J. Herrmann (1993). “The Intergroup Rhabdomyosarcoma Study-II”. Cancer. 71 (5): 1904–1922. PMID 8448756. Unknown parameter |month= ignored (help)

[76] W. Crist, E. A. Gehan, A. H. Ragab, P. S. Dickman, S. S. Donaldson, C. Fryer, D. Hammond, D. M. Hays, J. Herrmann & R. Heyn (1995). “The Third Intergroup Rhabdomyosarcoma Study”. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 13 (3): 610–630. doi:10.1200/JCO.1995.13.3.610. PMID 7884423. Unknown parameter |month= ignored (help)

[77] Michael C. G. Stevens, Annie Rey, Nathalie Bouvet, Caroline Ellershaw, Francoise Flamant, Jean Louis Habrand, H. Basil Marsden, Helene Martelli, Jose Sanchez de Toledo, Richard D. Spicer, David Spooner, Marie Jose Terrier-Lacombe, Adrian van Unnik & Odile Oberlin (2005). “Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology–SIOP Malignant Mesenchymal Tumor 89”. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23 (12): 2618–2628. doi:10.1200/JCO.2005.08.130. PMID 15728225. Unknown parameter |month= ignored (help)

[78] S. R. Months & R. B. Raney (1986). “Rhabdomyosarcoma of the head and neck in children: the experience at the Children’s Hospital of Philadelphia”. Medical and pediatric oncology. 14 (5): 288–292. PMID 3784981.

[79] J. Hicks & C. Flaitz (2002). “Rhabdomyosarcoma of the head and neck in children”. Oral oncology. 38 (5): 450–459. PMID 12110339. Unknown parameter |month= ignored (help)

[80] E. Shapiro & D. Strother (1992). “Pediatric genitourinary rhabdomyosarcoma”. The Journal of urology. 148 (6): 1761–1768. PMID 1433603. Unknown parameter |month= ignored (help)

[81] W. Jr Lawrence, D. M. Hays & T. E. Moon (1977). “Lymphatic metastasis with childhood rhabdomyosarcoma”. Cancer. 39 (2): 556–559. PMID 837339. Unknown parameter |month= ignored (help)

[82] W. Jr Lawrence, E. A. Gehan, D. M. Hays, M. Beltangady & H. M. Maurer (1987). “Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II)”. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 5 (1): 46–54. doi:10.1200/JCO.1987.5.1.46. PMID 3543238. Unknown parameter |month= ignored (help)

[83] E. S. Wiener, J. R. Anderson, J. I. Ojimba, T. E. Lobe, C. Paidas, R. J. Andrassy, R. B. Raney, S. J. Qualman, S. S. Donaldson, H. M. Maurer, M. P. Link, W. M. Crist & H. E. Grier (2001). “Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma?”. Seminars in pediatric surgery. 10 (3): 146–152. PMID 11481652. Unknown parameter |month= ignored (help)

[84] Khin Thway, Rashpal Flora, Chirag Shah, David Olmos & Cyril Fisher (2012). “Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors”. The American journal of surgical pathology. 36 (3): 462–469. doi:10.1097/PAS.0b013e3182417330. PMID 22301498. Unknown parameter |month= ignored (help)

[85] J. Rosai, M. Akerman, P. Dal Cin, I. DeWever, C. D. Fletcher, N. Mandahl, F. Mertens, F. Mitelman, A. Rydholm, R. Sciot, G. Tallini, H. Van den Berghe, W. Van de Ven, R. Vanni & H. Willen (1996). “Combined morphologic and karyotypic study of 59 atypical lipomatous tumors. Evaluation of their relationship and differential diagnosis with other adipose tissue tumors (a report of the CHAMP Study Group)”. The American journal of surgical pathology. 20 (10): 1182–1189. PMID 8827023. Unknown parameter |month= ignored (help)

[Dal_CinKools1993-86] Dal Cin, Paola; Kools, Patrick; Sciot, Raf; De Wever, Ivo; Van Damme, Boudewijn; Van de Ven, Wim; Van Den Berghe, Herman (1993). “Cytogenetic and fluorescence in situ hybridization investigation of ring chromosomes characterizing a specific pathologic subgroup of adipose tissue tumors”. Cancer Genetics and Cytogenetics. 68 (2): 85–90. doi:10.1016/0165-4608(93)90001-3. ISSN 0165-4608.

[Dei_TosDoglioni2000-87] Dei Tos, Angelo P.; Doglioni, Claudio; Piccinin, Sara; Sciot, Raf; Furlanetto, Alberto; Boiocchi, Mauro; Dal Cin, Paola; Maestro, Roberta; Fletcher, Christopher D. M.; Tallini, Giovanni (2000). “Coordinated expression and amplification of theMDM2,CDK4, andHMGI-C genes in atypical lipomatous tumours”. The Journal of Pathology. 190 (5): 531–536. doi:10.1002/(SICI)1096-9896(200004)190:5<531::AID-PATH579>3.0.CO;2-W. ISSN 0022-3417.

[Dei_Tos2000-88] Dei Tos, A (2000). “Liposarcoma: New entities and evolving concepts”. Annals of Diagnostic Pathology. 4 (4): 252–266. doi:10.1053/adpa.2000.8133. ISSN 1092-9134.

[89] M. D. Kraus, L. Guillou & C. D. Fletcher (1997). “Well-differentiated inflammatory liposarcoma: an uncommon and easily overlooked variant of a common sarcoma”. The American journal of surgical pathology. 21 (5): 518–527. PMID 9158675. Unknown parameter |month= ignored (help)

[90] P. Argani, F. Facchetti, G. Inghirami & J. Rosai (1997). “Lymphocyte-rich well-differentiated liposarcoma: report of nine cases”. The American journal of surgical pathology. 21 (8): 884–895. PMID 9255251. Unknown parameter |month= ignored (help)

[91] H. L. Evans (1979). “Liposarcoma: a study of 55 cases with a reassessment of its classification”. The American journal of surgical pathology. 3 (6): 507–523. PMID 534388. Unknown parameter |month= ignored (help)

[92] A. P. Dei Tos, T. Mentzel, P. L. Newman & C. D. Fletcher (1994). “Spindle cell liposarcoma, a hitherto unrecognized variant of liposarcoma. Analysis of six cases”. The American journal of surgical pathology. 18 (9): 913–921. PMID 8067512. Unknown parameter |month= ignored (help)

[93] D. C. Dahlin, K. K. Unni & T. Matsuno (1977). “Malignant (fibrous) histiocytoma of bone–fact or fancy?”. Cancer. 39 (4): 1508–1516. PMID 192432. Unknown parameter |month= ignored (help)

[94] Laura M. 3rd Arnold, Sudeep D. Burman & Albert H. O-Yurvati (2010). “Diagnosis and management of primary pulmonary leiomyosarcoma”. The Journal of the American Osteopathic Association. 110 (4): 244–246. PMID 20430913. Unknown parameter |month= ignored (help)

[WilkinsonRollason2001-95] Wilkinson, N; Rollason, T P (2001). “Recent advances in the pathology of smooth muscle tumours of the uterus”. Histopathology. 39 (4): 331–341. doi:10.1046/j.1365-2559.2001.01300.x. ISSN 0309-0167.

[96] S. W. Bell, R. L. Kempson & M. R. Hendrickson (1994). “Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases”. The American journal of surgical pathology. 18 (6): 535–558. PMID 8179071. Unknown parameter |month= ignored (help)

[LaunonenVierimaa2001-97] Launonen, V.; Vierimaa, O.; Kiuru, M.; Isola, J.; Roth, S.; Pukkala, E.; Sistonen, P.; Herva, R.; Aaltonen, L. A. (2001). “Inherited susceptibility to uterine leiomyomas and renal cell cancer”. Proceedings of the National Academy of Sciences. 98 (6): 3387–3392. doi:10.1073/pnas.051633798. ISSN 0027-8424.

[McClainLeach1995-98] McClain, Kenneth L.; Leach, Charles T.; Jenson, Hal B.; Joshi, Vijay V.; Pollock, Brad H.; Parmley, Richard T.; DiCarlo, Frederick J.; Chadwick, Ellen Gould; Murphy, Sharon B. (1995). “Association of Epstein–Barr Virus with Leiomyosarcomas in Young People with AIDS”. New England Journal of Medicine. 332 (1): 12–18. doi:10.1056/NEJM199501053320103. ISSN 0028-4793.

[FangMatsumoto2004-99] Fang, Zhiwei; Matsumoto, Seiichi; Ae, Keisuke; Kawaguchi, Noriyoshi; Yoshikawa, Hideki; Ueda, Takafumi; Ishii, Takeshi; Araki, Nobuhito; Kito, Masashi (2004). “Postradiation soft tissue sarcoma: a multiinstitutional analysis of 14 cases in Japan”. Journal of Orthopaedic Science. 9 (3): 242–246. doi:10.1007/s00776-004-0768-5. ISSN 0949-2658.

[FuturiDonohoe2014-100] Futuri, S.; Donohoe, K.; Spaccavento, C.; Yudelman, I. (2014). “Rectal leiomyosarcoma: a rare and long-term complication of radiation therapy”. Case Reports. 2014 (oct14 1): bcr2014205240–bcr2014205240. doi:10.1136/bcr-2014-205240. ISSN 1757-790X.

[LynchDeters2003-101] Lynch, Henry T.; Deters, Carolyn A.; Hogg, David; Lynch, Jane F.; Kinarsky, Yulia; Gatalica, Zoran (2003). “Familial sarcoma”. Cancer. 98 (9): 1947–1957. doi:10.1002/cncr.11743. ISSN 0008-543X.

[YuTucker2009-102] Yu, C.-L.; Tucker, M. A.; Abramson, D. H.; Furukawa, K.; Seddon, J. M.; Stovall, M.; Fraumeni, J. F.; Kleinerman, R. A. (2009). “Cause-Specific Mortality in Long-Term Survivors of Retinoblastoma”. JNCI Journal of the National Cancer Institute. 101 (8): 581–591. doi:10.1093/jnci/djp046. ISSN 0027-8874.

[RodriguezFolpe2012-103] Rodriguez, Fausto J.; Folpe, Andrew L.; Giannini, Caterina; Perry, Arie (2012). “Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems”. Acta Neuropathologica. 123 (3): 295–319. doi:10.1007/s00401-012-0954-z. ISSN 0001-6322.

[ChoiKomurov2017-104] Choi, Kwangmin; Komurov, Kakajan; Fletcher, Jonathan S.; Jousma, Edwin; Cancelas, Jose A.; Wu, Jianqiang; Ratner, Nancy (2017). “An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system”. Scientific Reports. 7 (1). doi:10.1038/srep43315. ISSN 2045-2322.

[LiaoBooker2018-105] Liao, Chung-Ping; Booker, Reid C.; Brosseau, Jean-Philippe; Chen, Zhiguo; Mo, Juan; Tchegnon, Edem; Wang, Yong; Clapp, D. Wade; Le, Lu Q. (2018). “Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis”. Journal of Clinical Investigation. 128 (7): 2848–2861. doi:10.1172/JCI99424. ISSN 0021-9738.

[StaserYang2010-106] 106.0 ^106.1 Staser, K.; Yang, F.-C.; Clapp, D. W. (2010). “Mast cells and the neurofibroma microenvironment”. Blood. 116 (2): 157–164. doi:10.1182/blood-2009-09-242875. ISSN 0006-4971.

[MuirNeubauer2001-107] Muir, David; Neubauer, Debbie; Lim, Ingrid T.; Yachnis, Anthony T.; Wallace, Margaret R. (2001). “Tumorigenic Properties of Neurofibromin-Deficient Neurofibroma Schwann Cells”. The American Journal of Pathology. 158 (2): 501–513. doi:10.1016/S0002-9440(10)63992-2. ISSN 0002-9440.

[WilkinsonManson2004-108] Wilkinson, Lana M.; Manson, David; Smith, Charles R. (2004). “Best Cases from the AFIP”. RadioGraphics. 24 (suppl_1): S237–S242. doi:10.1148/rg.24si035170. ISSN 0271-5333.

[BernthalJones2013-109] Bernthal, Nicholas; Jones, Kevin; Monument, Michael; Liu, Ting; Viskochil, David; Randall, R. (2013). “Lost in Translation: Ambiguity in Nerve Sheath Tumor Nomenclature and Its Resultant Treatment Effect”. Cancers. 5 (4): 519–528. doi:10.3390/cancers5020519. ISSN 2072-6694.

[MautnerFriedrich2003-110] Mautner, V. F.; Friedrich, R. E.; von Deimling, A.; Hagel, C.; Korf, B.; Knöfel, M. T.; Wenzel, R.; Fünsterer, C. (2003). “Malignant peripheral nerve sheath tumours in neurofibromatosis type 1: MRI supports the diagnosis of malignant plexiform neurofibroma”. Neuroradiology. 45 (9): 618–625. doi:10.1007/s00234-003-0964-6. ISSN 0028-3940.

[ShenHarper1996-111] Shen, M H; Harper, P S; Upadhyaya, M (1996). “Molecular genetics of neurofibromatosis type 1 (NF1)”. Journal of Medical Genetics. 33 (1): 2–17. doi:10.1136/jmg.33.1.2. ISSN 1468-6244.

[RubinGutmann2005-112] Rubin, Joshua B.; Gutmann, David H. (2005). “Neurofibromatosis type 1 — a model for nervous system tumour formation?”. Nature Reviews Cancer. 5 (7): 557–564. doi:10.1038/nrc1653. ISSN 1474-175X.

[pmid18725954-113] Sailon AM, Cappuccino G, Hameed M, Fleegler EJ (2008). “Nodular fasciitis of the hand over the metacarpophalangeal joint: a case report”. Eplasty. 8: e38. PMC 2491338. PMID 18725954.

[EmoriShimizu2018-114] Emori, M; Shimizu, J; Murahashi, Y; Mizushima, E; Sugita, S; Hasegawa, T; Yamashita, T (2018). “Nodular fasciitis involving the palm”. The Annals of The Royal College of Surgeons of England. 100 (5): e128–e131. doi:10.1308/rcsann.2018.0061. ISSN 0035-8843.

[KubotaOkada2012-115] Kubota, Kensuke; Okada, Seiji; Maeda, Takeshi; Matsumoto, Yoshihiro; Sakamoto, Akio; Harimaya, Katsumi; Saiwai, Hirokazu; Kumamaru, Hiromi; Oda, Yoshinao; Iwamoto, Yukihide (2012). “Extradural Nodular Fasciitis Arising in the Spinal Canal”. Spine. 37 (2): E133–E137. doi:10.1097/BRS.0b013e318224568a. ISSN 0362-2436.

[pmid15716235-116] Plaza JA, Mayerson J, Wakely PE (2005). “Nodular fasciitis of the hand: a potential diagnostic pitfall in fine-needle aspiration cytopathology”. Am J Clin Pathol. 123 (3): 388–93. doi:10.1309/PWD0-HB51-1L3V-R56W. PMID 15716235.

[pmid20975584-117] Wagner LM, Gelfand MJ, Laor T, Ryckman FC, Al-Ghawi H, Bove KE (2011). “A welcome surprise: nodular fasciitis presenting as soft tissue sarcoma”. J Pediatr Hematol Oncol. 33 (4): 316–9. doi:10.1097/MPH.0b013e3181e88649. PMID 20975584.

[pmid19655607-118] Grobmyer SR, Knapik JA, Foss RM, Copeland EM, Hochwald SN (2009). “Nodular fasciitis: differential considerations and current management strategies”. Am Surg. 75 (7): 610–4. PMID 19655607.

[pmid9528235-119] Yamamoto H, Yamada N, Yamada I, Hashikawa K, Kagimoto K, Ookubo M; et al. (1998). “[A case of nodular fasciitis of the chest wall]”. Kyobu Geka. 51 (3): 246–9. PMID 9528235.

[pmid18330617-120] Chiarini L, Lo Russo L, Figurelli S, Procacci P, Rubini C, Lo Muzio L (2008). “Nodular fasciitis of the face: aesthetic considerations”. Aesthetic Plast Surg. 32 (3): 560–2. doi:10.1007/s00266-008-9136-8. PMID 18330617.

[pmid23769422-121] Oliveira AM, Chou MM (2014). “USP6-induced neoplasms: the biologic spectrum of aneurysmal bone cyst and nodular fasciitis”. Hum Pathol. 45 (1): 1–11. doi:10.1016/j.humpath.2013.03.005. PMID 23769422.

[pmid21826056-122] Erickson-Johnson MR, Chou MM, Evers BR, Roth CW, Seys AR, Jin L; et al. (2011). “Nodular fasciitis: a novel model of transient neoplasia induced by MYH9-USP6 gene fusion”. Lab Invest. 91 (10): 1427–33. doi:10.1038/labinvest.2011.118. PMID 21826056.

[123] . doi:10.4197/Med. 17-3.1 Check |doi= value (help). Missing or empty |title= (help)

[pmid20555348-124] Russell SB, Russell JD, Trupin KM, Gayden AE, Opalenik SR, Nanney LB; et al. (2010). “Epigenetically altered wound healing in keloid fibroblasts”. J Invest Dermatol. 130 (10): 2489–96. doi:10.1038/jid.2010.162. PMC 2939920. PMID 20555348.

[pmid17989729-125] Smith JC, Boone BE, Opalenik SR, Williams SM, Russell SB (2008). “Gene profiling of keloid fibroblasts shows altered expression in multiple fibrosis-associated pathways”. J Invest Dermatol. 128 (5): 1298–310. doi:10.1038/sj.jid.5701149. PMC 2933038. PMID 17989729.

[HuangMurphy2013-126] Huang, Chenyu; Murphy, George F.; Akaishi, Satoshi; Ogawa, Rei (2013). “Keloids and Hypertrophic Scars”. Plastic and Reconstructive Surgery Global Open. 1 (4): e25. doi:10.1097/GOX.0b013e31829c4597. ISSN 2169-7574.

[pmid21837678-127] Smoll NR (2012). “Relative survival of childhood and adult medulloblastomas and primitive neuroectodermal tumors (PNETs)”. Cancer. 118 (5): 1313–22. doi:10.1002/cncr.26387. PMID 21837678.

[pmid8129041-128] Eibl RH, Kleihues P, Jat PS, Wiestler OD (1994). “A model for primitive neuroectodermal tumors in transgenic neural transplants harboring the SV40 large T antigen”. Am J Pathol. 144 (3): 556–64. PMC 1887088. PMID 8129041.

[pmid1933879-129] Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P (1991). “p53 mutations in nonastrocytic human brain tumors”. Cancer Res. 51 (22): 6202–5. PMID 1933879.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

[20]

[21]

[22]

[23]

[24]

[25]

[26]

[27]

[28]

[29]

[30]

[31]

[32]

[33]

[34]

[35]

[36]

[37]

[38]

[39]

[40]

[41]

[42]

[43]

[44]

[45]

[46]

[47]

[48]

[49]

[50]

[51]

[52]

[53]

[54]

[55]

[56]

[57]

[58]

[59]

[60]

[61]

[62]

[63]

[64]

[65]

[66]

[67]

[68]

[69]

[70]

[71]

[72]

[73]

[74]

[75]

[76]

[77]

[78]

[79]

[80]

[81]

[82]

[83]

[84]

[85]

[86]

[87]

[88]

[89]

[90]

[91]

[92]

[93]

[94]

[95]

[96]

[97]

[98]

[99]

[100]

Health Dictionary

Desmoid tumor differential diagnosis

Introduction

Overview

Differentiating Desmoid tumor from other Diseases

Reference